

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 513/04, A61K 31/54		A1	(11) International Publication Number: WO 99/03861
			(43) International Publication Date: 28 January 1999 (28.01.99)
(21) International Application Number: PCT/DK98/00288 (22) International Filing Date: 30 June 1998 (30.06.98) (30) Priority Data: 0872/97 16 July 1997 (16.07.97) DK 0368/98 17 March 1998 (17.03.98) DK (71) Applicant: NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsvaerd (DK). (72) Inventors: NIELSEN, Flemming, Elmedlund; Furesø Parkvej 46, DK-2830 Virum (DK). HANSEN, John, Bondo; Langgaasem 3, DK-4450 Jyderup (DK). HANSEN, Holger, Claus; Annexgårdsparken 43, DK-3500 Værløse (DK). TAGMOSE, Tina, Møller; Farum Hovedgade 52, 204, DK-3520 Farum (DK). MOGENSEN, John, Patrick; Dybendalsvej 69, DK-2720 Vanløse (DK).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.	

(54) Title: FUSED 1,2,4-THIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE



(57) Abstract

1,2,4-Thiadiazine and 1,4-thiazine derivatives represented by formula (I) wherein A, B, D, R¹, R², R³ and R⁴ are defined in the description, compositions thereof and methods for preparing the compounds are described. The compounds are useful in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Fused 1,2,4-Thiadiazine Derivatives, their Preparation and UseFIELD OF THE INVENTION

5 The present invention relates to fused 1,2,4-thiadiazine derivatives, to methods for their preparation, to compositions comprising the compounds, to the use of these compounds as medicaments and their use in therapy e.g. in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system.

FO:

BACKGROUND OF THE INVENTION

Potassium channels play an important role in the physiological and pharmacological control of cellular membrane potential. Amongst the different types of potassium channels
15 are the ATP-sensitive (K_{ATP} -) channels which are regulated by changes in the intracellular concentration of adenosine triphosphate. The K_{ATP} -channels have been found in cells from various tissues such as cardiac cells, pancreatic cells, skeletal muscles, smooth muscles, central neurons and adenohypophysis cells. The channels have been associated with diverse cellular functions for example hormone secretion (insulin from pancreatic beta-
20 cells, growth hormone and prolactin from adenohypophysis cells), vasodilation (in smooth muscle cells), cardiac action potential duration, neurotransmitter release in the central nervous system.

Modulators of the K_{ATP} -channels have been found to be of importance for the treatment of
25 various diseases. Certain sulphonylureas which have been used for the treatment of non-insulin-dependent diabetes mellitus act by stimulating insulin release through an inhibition of the K_{ATP} -channels on pancreatic beta-cells.

The potassium channel openers, which comprise a heterogeneous group of compounds,
30 have been found to be able to relax vascular smooth muscles and have therefore been used for the treatment of hypertension.

In addition, potassium channel openers can be used as bronchodilators in the treatment of

asthma and various other diseases.

Furthermore, potassium channel openers have been shown to promote hairgrowth, and have been used for the treatment of baldness.

5

Potassium channel openers are also able to relax urinary bladder smooth muscle and therefore, can be used for the treatment of urinary incontinence. Potassium channel openers which relax smooth muscle of the uterus can be used for treatment of premature labor.

- 10 By acting on potassium channels of the central nervous system these compounds can be used for treatment of various neurological and psychiatric diseases such as Alzheimer, epilepsy and cerebral ischemia.

Further, the compounds are found to be useful in the treatment of benign prostatic

- 15 hyperplasia, erectile dysfunction and in contraception.

Compounds of the present invention, which inhibit insulin secretion by activating potassium channels of the beta-cell can be used in combination with other compounds which may be used to treat non-insulin dependent diabetes mellitus and insulin dependent
20 diabetes mellitus. Examples of such compounds are insulin, insulin sensitizers, such as thiazolidinediones, insulin secretagogues, such as repaglinide, tolbutamide, glibenclamide and glucagon like peptide (GLP1), inhibitors of α -glucosidases and hepatic enzymes responsible for the biosynthesis of glucose.

- 25 Recently, it has been shown that Diazoxide (7-chloro-3-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide) and certain 3-(alkylamino)-4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxide derivatives inhibit insulin release by an activation of K_{ATP} -channels on pancreatic beta-cells (Pirotte B. et al. *Biochem. Pharmacol.* **47**, 1381-1386 (1994); Pirotte B. et al., *J. Med. Chem.*, **36**, 3211-3213 (1993). Diazoxide has furthermore been shown to delay the
30 onset of diabetes in BB-rats (Vlahos WD et al. *Metabolism* **40**, 39-46 (1991)). In obese zucker rats diazoxide has been shown to decrease insulin secretion and increase insulin receptor binding and consequently improve glucose tolerance and decrease weight gain


(Alemzadeh R. et al. Endocrinol. 133, 705-712; 1993). It is expected that compounds which activate K_{ATP} -channels can be used for treatment of diseases characterised by an overproduction of insulin and for the treatment and prevention of diabetes.

- 5 EP 618 209 discloses a class of pyridothiadiazine derivatives having an alkyl or an alkylamino group in position 3 of the thiadiazine ring. These compounds are claimed to be agonists at the AMPA-glutamate receptor.

In J. Med. Chem. 1980, 23, 575-577 the synthesis of 4(5)-amino- and formylaminoimidazo-
 10 5(4) carboxamide and their properties as agents of chemotherapeutic value are described. Especially, the compounds 3-aminoimidazo[4,5-e]-1,2,4-thiadiazine 1,1-dioxide and N-benzoylaminoimidazo[4,5-e]-1,2,4-thiadiazine 1,1-dioxide are shown.

15 DESCRIPTION OF THE INVENTION

The present invention relates to fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives of the general formula I:



25

wherein

B represents $>NR^5$ or $>CR^5R^6$, wherein R^5 and R^6 independently are hydrogen; hydroxy; C_{1-6} -alkoxy; or C_{1-6} -alkyl, C_{3-6} -cycloalkyl, C_{2-6} -alkenyl or C_{2-6} -alkynyl optionally mono- or

polysubstituted with halogen; or R⁵ and R⁴ together represent one of the bonds in a double bond between the atoms 2 and 3 of formula I;

D represents -S(=O)₂- or -S(=O)-; or

5

D-B represents -S(=O)(R⁷)=N-

wherein R⁷ is C₁₋₆-alkyl; or aryl or heteroaryl optionally mono- or polysubstituted with halogen, hydroxy, C₁₋₆-alkoxy, aryloxy, arylalkoxy, nitro, amino, C₁₋₆-monoalkyl- or
10 dialkylamino, cyano, acyl, or C₁₋₆-alkoxycarbonyl;

R¹ is hydrogen; hydroxy; C₁₋₆-alkoxy; or C₁₋₆-alkyl, C₃₋₆-cycloalkyl, C₂₋₆-alkenyl or C₂₋₆-alkynyl optionally mono- or polysubstituted with halogen and R⁴ is hydrogen; or R⁴ together with R⁵ represent one of the bonds in a double bond between the atoms 2 and 3
15 of formula I; or R¹ together with R⁴ represent one of the bonds in a double bond between the atoms 3 and 4 of formula I;

R² is hydrogen; hydroxy; C₁₋₆-alkoxy; or C₁₋₆-alkyl, C₃₋₆-cycloalkyl, C₂₋₆-alkenyl or C₂₋₆-alkynyl optionally mono- or polysubstituted with halogen;

20

R³ is R⁸; -OR⁸; -C(=X)R⁸; -NR⁸R⁹; bicycloalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl optionally mono- or polysubstituted with halogen, hydroxy, C₁₋₆-alkoxy, aryloxy, arylalkoxy, nitro, amino, C₁₋₆-monoalkyl- or dialkylamino, cyano, oxo, acyl or C₁₋₆-alkoxycarbonyl; or aryl substituted with C₁₋₆-alkyl;


25

wherein R⁸ is hydrogen; C₃₋₆-cycloalkyl or (C₃₋₆-cycloalkyl)C₁₋₆-alkyl, the C₃₋₆-cycloalkyl group optionally being mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; a 3-6 membered saturated ring system comprising one or more nitrogen-, oxygen- or sulfur atoms; or straight or branched C₁₋₁₈-alkyl optionally mono- or polysubstituted with
30 halogen, hydroxy, C₁₋₆-alkoxy, C₁₋₆-alkylthio, C₃₋₆-cycloalkyl, aryl, aryloxy, arylalkoxy, nitro, amino, C₁₋₆-monoalkyl- or dialkylamino, cyano, oxo, formyl, acyl, carboxy, C₁₋₆-alkoxy-carbonyl, or carbamoyl;

X is O or S;

R⁹ is hydrogen; C₁₋₆-alkyl; C₂₋₆-alkenyl; C₃₋₆-cycloalkyl optionally mono- or polysubstituted
5 with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; or

R⁸ and R⁹ together with the nitrogen atom form a 3-12 membered mono- or bicyclic
system, in which one or more of the carbon atoms may be exchanged with nitrogen,
oxygen or sulfur, each of these ring systems optionally being mono- or polysubstituted
10 with halogen, C₁₋₆-alkyl, hydroxy, C₁₋₆-alkoxy, C₁₋₆-alkoxy-C₁₋₆-alkyl, nitro, amino, cyano,
trifluoromethyl, C₁₋₆-monoalkyl- or dialkylamino, oxo; or R³ is



15

wherein n,m,p independently are 0,1,2,3 and R¹⁰ is hydrogen; hydroxy; C₁₋₆-alkoxy; C₃₋₆-
cycloalkyl optionally mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-
alkoxy; C₁₋₆-alkyl, C₂₋₆-alkenyl or C₂₋₆-alkynyl optionally mono- or polysubstituted with
halogen; or

20

R² and R³ together with the nitrogen atom forms a 3-12 membered mono- or bicyclic
system, in which one or more of the carbon atoms may be exchanged with nitrogen,
oxygen or sulfur, each of these ring systems optionally being mono- or polysubstituted
with halogen, C₁₋₆-alkyl, hydroxy, C₁₋₆-alkoxy, C₁₋₆-alkoxy-C₁₋₆-alkyl, nitro, amino, cyano,
25 trifluoromethyl, C₁₋₆-monoalkyl- or dialkylamino or oxo;

A together with carbon atoms 5 and 6 of formula I represents a 5 or 6 membered hetero-
cyclic system comprising one or more nitrogen-, oxygen- or sulfur atoms, the heterocyclic

systems optionally being mono- or polysubstituted with halogen; C₁₋₁₂-alkyl; C₃₋₆-cycloalkyl; hydroxy; C₁₋₆-alkoxy; C₁₋₆-alkoxy-C₁₋₆-alkyl; nitro; amino; cyano; cyanomethyl; perhalomethyl; C₁₋₆-monoalkyl- or dialkylamino; sulfamoyl; C₁₋₆-alkylthio; C₁₋₆-alkylsulfonyl; C₁₋₆-alkylsulfinyl; C₁₋₆-alkylcarbonylamino; arylthio, arylsulfinyl, arylsulfonyl, the aryl group
 5 optionally being mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; C₁₋₆-alkoxycarbonyl; C₁₋₆-alkoxycarbonyl-C₁₋₆-alkyl; carbamyl; carbamyl- methyl; C₁₋₆-monoalkyl- or dialkylaminocarbonyl; C₁₋₆-monoalkyl- or dialkylaminothiocarbonyl; ureido; C₁₋₆-monoalkyl- or dialkylaminocarbonylamino, thioureido; C₁₋₆-monoalkyl- or dialkylaminothiocarbonyl- amino; C₁₋₆-monoalkyl- or dialkylaminosulfonyl; carboxy; carboxy-C₁₋₆-
 10 alkyl; acyl; aryl, arylalkyl, aryloxy, the aryl group optionally being mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; (1,2,4-oxadiazol-5-yl)- or (1,2,4-oxadiazol-3-yl)-C₁₋₆-alkyl the oxadiazolyl group optionally being substituted with C₁₋₆-alkyl or C₃₋₆-cycloalkyl; or a 5 - 6 membered nitrogen containing ring, optionally substituted with phenyl or C₁₋₆-alkyl;

15

provided that A together with carbon atoms 5 and 6 of formula I do not form a pyridine ring and that the following compounds 3-aminoimidazo[4,5-e]-1,2,4-thiadiazine 1,1-dioxide and 3- (benzoylamino)imidazo[4,5-e]-1,2,4-thiadiazine 1,1-dioxide are not included;

20 or a salt thereof with a pharmaceutically acceptable acid or base.

Within its scope the invention includes all optical isomers of compounds of formula I, some of which are optically active, and also their mixtures including racemic mixture thereof.

25 The scope of the invention also includes all tautomeric forms of the compounds of formula I.

The salts include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable metal salts or optionally alkylated ammonium salts, such as hydrochloric,
 30 hydrobromic, hydroiodic, phosphoric, sulfuric, trifluoroacetic, trichloroacetic, oxalic, maleic, pyruvic, malonic, succinic, citric, tartaric, fumaric, mandelic, benzoic, cinnamic, methane-sulfonic, ethane sulfonic, picric and the like, and include acids related to the pharmaceuti-

cally acceptable salts listed in Journal of Pharmaceutical Science, 66, 2 (1977) and incorporated herein by reference, or lithium, sodium, potassium, magnesium and the like.

The term "C₁₋₆-alkoxy" as used herein, alone or in combination, refers to a straight or
5 branched monovalent substituent comprising a C₁₋₆-alkyl group linked through an ether oxygen having its free valence bond from the ether oxygen and having 1 to 6 carbon atoms e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, pentoxy.

The term "C₁₋₆-alkylthio" as used herein, alone or in combination, refers to a straight or
10 branched monovalent substituent comprising a lower alkyl group linked through a divalent sulfur atom having its free valence bond from the sulfur atom and having 1 to 6 carbon atoms e.g. methylthio, ethylthio, propylthio, butylthio, pentylthio.

The term "C₂₋₆-alkenyl" as used herein refers to an unsaturated hydrocarbon chain having
15 2-6 carbon atoms and one double bond such as e.g. vinyl, 1-propenyl, allyl, isopropenyl, n-butenyl, n-pentenyl and n-hexenyl.

The term "C₃₋₆-cycloalkyl" as used herein refers to a radical of a saturated cyclic hydrocarbon with the indicated number of carbons such as cyclopropyl, cyclobutyl, cyclopentyl, or
20 cyclohexyl.

The term "C₂₋₆-alkynyl" as used herein refers to unsaturated hydrocarbons which contain triple bonds, such as e.g. -C≡CH, -C≡CCH₃, -CH₂C≡CH, -CH₂CH₂C≡CH, -CH(CH₃)C≡CH, and the like.

25

The term "C₁₋₆-alkoxy-C₁₋₆-alkyl" as used herein refers to a group of 2-12 carbon atoms interrupted by an O such as e.g. CH₂-O-CH₃, CH₂-O-CH₂-CH₃, CH₂-O-CH(CH₃)₂ and the like.

30 The term "halogen" means fluorine, chlorine, bromine or iodine.

The term "perhalomethyl" means trifluoromethyl, trichloromethyl, tribromomethyl or

triiodomethyl.

The terms "C₁₋₆-alkyl", "C₁₋₁₂-alkyl" and "C₁₋₁₈-alkyl" as used herein, alone or in combination, refers to a straight or branched, saturated hydrocarbon chain having the indicated number
5 of carbon atoms such as e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, 4-methylpentyl, neopentyl, n-hexyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1,2,2-trimethylpropyl and the like. The term "C₁₋₁₈-alkyl" as used herein also includes secondary C₃₋₆-alkyl and tertiary C₄₋₆-alkyl.

10 The term "C₁₋₆-monoalkylamino" as used herein refers to an amino group wherein one of the hydrogen atoms is substituted with a straight or branched, saturated hydrocarbon chain having the indicated number of carbon atoms such as e.g. methylamino, ethylamino, propylamino, n-butylamino, sec-butylamino, isobutylamino, tert-butylamino, n-pentylamino, 2-methylbutylamino, n-hexylamino, 4-methylpentylamino, neopentylamino, n-hexylamino,
15 2,2-dimethylpropylamino and the like.

The term "C₁₋₆-dialkylamino" as used herein refers to an amino group wherein the two hydrogen atoms independently are substituted with a straight or branched, saturated hydrocarbon chain having the indicated number of carbon atoms; such as dimethylamino,
20 N-ethyl-N-methylamino, diethylamino, dipropylamino, N-(n-butyl)-N-methylamino, di(n-pentyl)amino, and the like.

The term "acyl" as used herein refers to a monovalent substituent comprising a C₁₋₆-alkyl group linked through a carbonyl group; such as e.g. acetyl, propionyl, butyryl, isobutyryl,
25 pivaloyl, valeryl, and the like.

The term "C₁₋₆-alkoxycarbonyl" as used herein refers to a monovalent substituent comprising a C₁₋₆-alkoxy group linked through a carbonyl group; such as e.g. methoxycarbonyl, carbethoxy, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, sec-
30 butoxycarbonyl, tert-butoxycarbonyl, 3-methylbutoxycarbonyl, n-hexoxycarbonyl and the like.

The term "3-12 membered mono- or bicyclic system" as used herein refers to a monovalent substituent of formula $-NR^2R^3$ or $-NR^8R^9$ where R^2 and R^3 , or R^8 and R^9 together with the nitrogen atom form a 3-12 membered mono- or bicyclic system, in which one or more of the carbon atoms may be exchanged with nitrogen, oxygen or sulfur, such as 1-pyrrolidyl, piperidino, morpholino, thiomorpholino, 4-methylpiperazin-1-yl, 7-azabicyclo[2.2.1]heptan-7-yl, tropanyl and the like.

The term "3-6 membered saturated ring system" as used herein refers to a monovalent substituent comprising a monocyclic saturated system containing one or more hetero atoms selected from nitrogen, oxygen and sulfur and having 3-6 members and having its free valence from a carbon atom, e.g. 2-pyrrolidyl, 4-piperidyl, 3-morpholinyl, 1,4-dioxan-2-yl, 5-oxazolidinyl, 4-isoxazolidinyl, or 2-thiomorpholinyl.

The term "bicycloalkyl" as used herein refers to a monovalent substituent comprising a bicyclic structure made of 6-12 carbon atoms such as e.g. 2-norbornyl, 7-norbornyl, 2-bicyclo[2.2.2]octyl, and 9-bicyclo[3.3.1]nonanyl.

The term "aryl" as used herein refers to phenyl, 1-naphthyl, or 2-naphthyl.

The term "heteroaryl" as used herein, alone or in combination, refers to a monovalent substituent comprising a 5-6 membered monocyclic aromatic system or a 9-10 membered bicyclic aromatic system containing one or more heteroatoms selected from nitrogen, oxygen and sulfur, e.g. pyrrole, imidazole, pyrazole, triazole, pyridine, pyrazine, pyrimidine, pyridazine, isothiazole, isoxazole, oxazole, oxadiazole, thiadiazole, quinoline, isoquinoline, quinazoline, quinoxaline, indole, benzimidazole, benzofuran, pteridine, and purine.

The term "arylalkyl" as used herein refers to a straight or branched saturated carbon chain containing from 1 to 6 carbons substituted with an aromatic carbohydride; such as benzyl, phenethyl, 3-phenylpropyl, 1-naphthylmethyl, 2-(1-naphthyl)ethyl and the like.

The term "aryloxy" as used herein refers to phenoxy, 1-naphthyloxy or 2-naphthyloxy.

The term "arylalkoxy" as used herein refers to a C₁₋₆-alkoxy group substituted with an aromatic carbohydride, such as benzyloxy, phenethoxy, 3-phenylpropoxy, 1-naphthylmethoxy, 2-(1-naphthyl)ethoxy and the like.

5

The term "heteroarylalkyl" as used herein refers to a straight or branched saturated carbon chain containing from 1 to 6 carbons substituted with a heteroaryl group; such as (2-furyl)methyl, (3-furyl)methyl, (2-thienyl)methyl, (3-thienyl)methyl, (2-pyridyl)methyl, 1-methyl-1-(2-pyrimidyl)ethyl and the like.

10

The term "C₁₋₆-alkylsulfonyl" as used herein refers to a monovalent substituent comprising a C₁₋₆-alkyl group linked through a sulfonyl group such as e.g. methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, isopropylsulfonyl, n-butylsulfonyl, sec-butylsulfonyl, isobutylsulfonyl, tert-butylsulfonyl, n-pentylsulfonyl, 2-methylbutylsulfonyl, 3-methylbutylsulfonyl, n-hexylsulfonyl, 4-methylpentylsulfonyl, neopentylsulfonyl, n-hexylsulfonyl and 2,2-dimethylpropylsulfonyl.

The term "C₁₋₆-monoalkylaminosulfonyl" as used herein refers to a monovalent substituent comprising a C₁₋₆-monoalkylamino group linked through a sulfonyl group such as e.g. methylaminosulfonyl, ethylaminosulfonyl, n-propylaminosulfonyl, isopropylaminosulfonyl, n-butylaminosulfonyl, sec-butylaminosulfonyl, isobutylaminosulfonyl, tert-butylaminosulfonyl, n-pentylaminosulfonyl, 2-methylbutylaminosulfonyl, 3-methylbutylaminosulfonyl, n-hexylaminosulfonyl, 4-methylpentylaminosulfonyl, neopentylaminosulfonyl, n-hexylaminosulfonyl and 2,2-dimethylpropylaminosulfonyl.

25

The term "C₁₋₆-dialkylaminosulfonyl" as used herein refers to a monovalent substituent comprising a C₁₋₆-dialkylamino group linked through a sulfonyl group such as dimethylaminosulfonyl, N-ethyl-N-methylaminosulfonyl, diethylaminosulfonyl, dipropylaminosulfonyl, N-(n-butyl)-N-methylaminosulfonyl, di(n-pentyl)aminosulfonyl, and the like.

30

The term "C₁₋₆-alkylsulfinyl" as used herein refers to a monovalent substituent comprising a straight or branched C₁₋₆-alkyl group linked through a sulfinyl group (-S(=O)-); such as e.g.

methysulfinyl, ethylsulfinyl, isopropylsulfinyl, butylsulfinyl, pentylsulfinyl, and the like.

The term "C₁₋₆-alkylcarbonylamino" as used herein refers to an amino group wherein one of the hydrogen atoms is substituted with an acyl group, such as e.g. acetamido, propionamido, isopropylcarbonylamino, and the like.

The term "(C₃₋₆-cycloalkyl)C₁₋₆-alkyl" as used herein, alone or in combination, refers to a straight or branched, saturated hydrocarbon chain having 1 to 6 carbon atoms and being monosubstituted with a C₃₋₆-cycloalkyl group, the cycloalkyl group optionally being mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; such as e.g. cyclopropylmethyl, (1-methylcyclopropyl)methyl, 1-(cyclopropyl)ethyl, cyclopentylmethyl, cyclohexylmethyl, and the like.

The term "arylthio" as used herein, alone or in combination, refers to an aryl group linked through a divalent sulfur atom having its free valence bond from the sulfur atom, the aryl group optionally being mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; e.g. phenylthio, (4-methylphenyl)-thio, (2-chlorophenyl)thio, and the like.

The term "arylsulfinyl" as used herein refers to an aryl group linked through a sulfinyl group (-S(=O)-), the aryl group optionally being mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; such as e.g. phenylsulfinyl, (4-chlorophenyl)sulfinyl, and the like.

The term "arylsulfonyl" as used herein refers to an aryl group linked through a sulfonyl group, the aryl group optionally being mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; such as e.g. phenylsulfonyl, tosyl, and the like.

The term "C₁₋₆-monoalkylaminocarbonyl" as used herein refers to a monovalent substituent comprising a C₁₋₆-monoalkylamino group linked through a carbonyl group such as e.g. methylaminocarbonyl, ethylaminocarbonyl, n-propylaminocarbonyl, isopropylaminocarbonyl, n-butylaminocarbonyl, sec-butylaminocarbonyl, isobutylaminocarbonyl, tert-butylaminocarbonyl, n-pentylaminocarbonyl, 2-methylbutylaminocarbonyl, 3-methylbutylamino-carbonyl, n-hexylaminocarbonyl, 4-methylpentylaminocarbonyl, neo-

pentylaminocarbonyl, n-hexylaminocarbonyl and 2-2-dimethylpropylaminocarbonyl.

The term "C₁₋₆-dialkylaminocarbonyl" as used herein refers to a monovalent substituent comprising a C₁₋₆-dialkylamino group linked through a carbonyl group such as dimethylaminocarbonyl, N-ethyl-N-methylaminocarbonyl, diethylaminocarbonyl, dipropylaminocarbonyl, N-(n-butyl)-N-methylaminocarbonyl, di(n-pentyl)aminocarbonyl, and the like.

The term "C₁₋₆-monoalkylaminocarbonylamino" as used herein refers to an amino group wherein one of the hydrogen atoms is substituted with a C₁₋₆-monoalkylaminocarbonyl group, e.g. methylaminocarbonylamino, ethylaminocarbonylamino, n-propylaminocarbonylamino, isopropylaminocarbonylamino, n-butylaminocarbonylamino, sec-butylaminocarbonylamino, isobutylaminocarbonylamino, tert-butylaminocarbonylamino, and 2-methylbutylaminocarbonylamino.

The term "C₁₋₆-dialkylaminocarbonylamino" as used herein refers to an amino group wherein one of the hydrogen atoms is substituted with a C₁₋₆-dialkylaminocarbonyl group, such as dimethylaminocarbonylamino, N-ethyl-N-methylaminocarbonylamino, diethylaminocarbonylamino, dipropylaminocarbonylamino, N-(n-butyl)-N-methylaminocarbonylamino, di(n-pentyl)aminocarbonylamino, and the like.


20

The term "5- or 6-membered heterocyclic system" as used herein refers to: a monocyclic unsaturated or saturated system containing one, two or three hetero atoms selected from nitrogen, oxygen and sulfur and having 5 members, e.g. pyrrole, furan, thiophene, pyrroline, dihydrofuran, dihydrothiophene, imidazole, imidazoline, pyrazole, pyrazoline, oxazole, thiazole, isoxazole, isothiazole, 1,2,3-oxadiazole, furazan, 1,2,3-triazole, 1,2,3-thiadiazole or 2,1,3-thiadiazole; an aromatic monocyclic system containing two or more nitrogen atoms and having 6 members, e.g. pyrazine, pyrimidine, pyridazine, 1,2,4-triazine, 1,2,3-triazine or tetrazine; a non-aromatic monocyclic system containing one or more hetero atoms selected from nitrogen, oxygen and sulfur and having 6 members, e.g. pyran, thiopyran, piperidine, dioxane, oxazine, isoxazine, dithiane, oxathine, thiazine, piperazine, thiadiazine, dithiazine or oxadiazine.

30

The term "5- or 6-membered nitrogen containing ring" as used herein refers to a monovalent substituent comprising a monocyclic unsaturated or saturated system containing one or more nitrogen atoms and having 5 or 6 members, e.g. pyrrolidinyl, pyrrolinyl, imidazolidinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, pyrrolyl, 2H-pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, morpholino, thiomorpholino, isothiazolyl, isoxazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, 1,3-dioxolanyl, and 1,4-dioxolanyl.

In a preferred embodiment of the invention the general formula of formula I is selected from



15

wherein

R¹ and R⁵ independently are hydrogen; hydroxy; C₁₋₆-alkoxy; or C₁₋₆-alkyl, C₃₋₆-cycloalkyl, C₂₋₆-alkenyl or C₂₋₆-alkynyl optionally mono- or polysubstituted with halogen and R⁴ is hydrogen; or

20

R⁴ together with R⁵ represent one of the bonds in a double bond between the atoms 2 and 3 of formula I and R¹ is as defined above; or


R⁴ together with R¹ represent one of the bonds in a double bond between the atoms 3 and 4 of formula I and R⁵ is as defined above;

14

D represents $-S(=O)_2-$ or $-S(=O)-$.

In another preferred embodiment of the invention the general formula of formula I is selected from

5



wherein

R¹ is hydrogen; hydroxy; C₁₋₆-alkoxy; or C₁₋₆-alkyl, C₃₋₆-cycloalkyl, C₂₋₆-alkenyl or C₂₋₆-alkynyl optionally mono- or polysubstituted with halogen and R⁴ is hydrogen; or

10

R⁴ together with R¹ represent one of the bonds in a double bond between the atoms 3 and 4 of formula I;


15 D represents $-S(=O)R^7=$

wherein R⁷ is C₁₋₆-alkyl; or aryl or heteroaryl optionally mono- or polysubstituted with halogen, hydroxy, C₁₋₆-alkoxy, aryloxy, arylalkoxy, nitro, amino, C₁₋₆-monoalkyl- or dialkylamino, cyano, acyl or C₁₋₆-alkoxycarbonyl.

20

In another preferred embodiment of the invention the general formula of formula I is selected from

15



wherein

- 5 R¹, R⁵ and R⁶ independently are hydrogen; hydroxy; C₁₋₆-alkoxy; or C₁₋₆-alkyl, C₃₋₆-cycloalkyl, C₂₋₆-alkenyl or C₂₋₆-alkynyl optionally mono- or polysubstituted with halogen and R⁴ is hydrogen; or

R⁴ together with R⁵ represent one of the bonds in a double bond between the atoms 2 and 10 3 of formula I and R¹ and R⁶ are as defined above; or

R⁴ together with R¹ represent one of the bonds in a double bond between the atoms 3 and 4 of formula I and R⁵ and R⁶ are as defined above;

- 15 D represents -S(=O)₂- or S(=O).

Preferably, the general formula of formula I is (Ia).

In another preferred embodiment of the invention D is -S(=O)₂-.

20

In another preferred embodiment of the invention R¹ is selected from hydrogen, C₁₋₆-alkyl, C₃₋₆-cycloalkyl or C₂₋₆-alkenyl. Preferably R¹ is hydrogen or C₁₋₆-alkyl.

In another preferred embodiment of the invention R¹ together with R⁴ represent one of the 25 bonds in a double bond between the atoms 3 and 4 of formula I.

In another preferred embodiment of the invention R⁴ together with R⁵ represent one of the bonds in a double bond between the atoms 2 and 3 of formula I.

In another preferred embodiment of the invention R^2 is selected from hydrogen, hydroxy, C_{1-6} -alkyl, C_{3-6} -cycloalkyl or C_{2-6} -alkenyl. Preferably R^2 is hydrogen or C_{1-6} -alkyl.

5 In another preferred embodiment of the invention R^3 is selected from R^8 , $-OR^8$, $-NR^8R^9$ or aryl, the aryl group optionally being substituted with C_{1-6} -alkyl; wherein R^8 is hydrogen; C_{3-6} -cycloalkyl; (C_{3-6} -cycloalkyl) C_{1-6} -alkyl; a 3-6-membered saturated ring system comprising one, two or three nitrogen-, oxygen- or sulfur atoms; or straight or branched C_{1-18} -alkyl optionally substituted with halogen, hydroxy, C_{1-6} -alkoxy, C_{1-6} -alkylthio, C_{3-6} -cycloalkyl or
10 aryl; R^9 is hydrogen, C_{1-6} -alkyl or C_{3-6} -cycloalkyl; or R^8 and R^9 together with the nitrogen atom form a 4 - 6 membered ring, preferably 1-pyrrolidyl, piperidine or morpholino.

In yet another preferred embodiment of the invention R^3 is selected from secondary C_{3-6} -alkyl, tertiary C_{4-6} -alkyl, C_{3-6} -cycloalkyl or (C_{3-6} -cycloalkyl)methyl optionally mono- or
15 polysubstituted with C_{1-6} -alkyl, halogen, hydroxy or C_{1-6} -alkoxy. Preferably R^3 is selected from isopropyl, 1-methylpropyl, 2-methylpropyl, tert-butyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1,2,2-trimethylpropyl, 2,3-dimethylbutyl, 1-ethylpropyl, 1-ethyl-2-methylpropyl, 1-ethyl-2,2-dimethylpropyl, 2,3,3-trimethylbutyl, 2-methylbutyl, 1,5-dimethylhexyl, 3-methylbutyl, 3-methylhexyl, cyclopropyl, 1-methylcyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopro-
20 pylmethyl, 1-(cyclopropyl)ethyl cyclobutylmethyl, cyclopentylmethyl or cyclohexylmethyl.

In a further preferred embodiment of the invention R^2 and R^3 together with the nitrogen atom forms a six membered ring, optionally substituted in the 2-position with a C_{1-6} -alkyl group, preferably selected from methyl, ethyl or isopropyl. Preferably the six membered
25 ring is a piperidine, piperazine, morpholine or thiomorpholine ring.

In another preferred embodiment of the invention R^7 is selected from C_{1-6} -alkyl, phenyl or pyridyl.

30 In another preferred embodiment of the invention A forms together with carbon atoms 5 and 6 of formula I a 5 membered heterocyclic system containing one hetero atom selected from nitrogen and sulfur, a 5 membered heterocyclic system containing two hetero atoms

selected from nitrogen, oxygen and sulfur, a 6 membered aromatic heterocyclic system containing two or three nitrogen atoms, a 6 membered non-aromatic heterocyclic system containing one or two hetero atoms selected from nitrogen, oxygen and sulfur; the heterocyclic systems optionally being mono- or disubstituted with halogen; C₁₋₁₂-alkyl; C₃₋₆-cycloalkyl; cyano; cyanomethyl; perhalomethyl; sulfamoyl; C₁₋₆-alkylthio; C₁₋₆-alkylsulfonyl; C₁₋₆-alkylsulfinyl; arylthio, arylsulfinyl, arylsulfonyl, the aryl group optionally being mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; C₁₋₆-alkoxycarbonyl-C₁₋₆-alkyl; carbamylmethyl; carboxy-C₁₋₆-alkyl; aryloxy; (1,2,4-oxadiazol-5-yl)- or (1,2,4-oxadiazol-3-yl)C₁₋₆-alkyl, the oxadiazolyl group optionally being substituted with C₁₋₆-alkyl or C₃₋₆-cycloalkyl; acyl; or a 5 - 6 membered nitrogen containing ring, optionally substituted with phenyl or C₁₋₆-alkyl.

Preferably, A forms together with carbon atoms 5 and 6 a thieno[3,2-e]- or pyrrolo[3,2-e]-ring, thiophene, imidazole, thiazole, pyrazole, isoxazole or isothiazole, a pyrazino[2,3-e]-, a pyrimido[4,5-e]-, a pyrimido[5,4-e]-, a pyridazino[4,5-e]- or a pyridazino[4,3-e]-ring, thiopyran, piperidine, dioxane, oxazine or dithiane.

Preferred compounds of the invention are:

- 20 7-Cyano-3-isopropylamino-6-methyl-4H-thieno[2,3-e]-1,2,4-thiadiazine 1,1-dioxide
- 7-Cyano-6-methyl-3-propylamino-4H-thieno[2,3-e]-1,2,4-thiadiazine 1,1-dioxide
- 6-Chloro-3-isopentylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
- 6-Chloro-3-(1-methylheptyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
- 6-Chloro-3-(1-ethylpentyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
- 25 6-Chloro-3-(2-methylbutyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
- 6-Chloro-3-(1-methylhexyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
- 6-Chloro-3-cyclopentylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
- 6-Chloro-3-cyclohexylmethylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
- Ethyl 3-(6-chloro-1,4-dihydro-1,1-dioxothieno[3,2-e]-1λ⁶,2,4-thiadiazin-3-ylamino)butanoate
- 30 3-(6-Chloro-1,4-dihydro-1,1-dioxothieno[3,2-e]-1λ⁶,2,4-thiadiazin-3-ylamino)butanoic acid
- 6-Chloro-3-(3-hydroxy-1-methylpropyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-

dioxide

- (R)-6-Chloro-3-(1-phenylethyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
 (S)-3-sec-Butylamino-6-chloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
 6-Chloro-3-isopropylamino-4H-thieno[2,3-e]-1,2,4-thiadiazine 1,1-dioxide
 5 6-Chloro-3-cyclopentylamino-4H-thieno[2,3-e]-1,2,4-thiadiazine 1,1-dioxide
 6-Bromo-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
 3-Isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
 6-Fluoro-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
 3-Cyclobutylamino-5,6-dimethyl-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
 10 3-Cyclopentylamino-5,6-dimethyl-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
 3-Isopropylamino-6,7-dimethyl-4H-thieno[2,3-e]-1,2,4-thiadiazine 1,1-dioxide
 3-Cyclobutylamino-6,7-dimethyl-4H-thieno[2,3-e]-1,2,4-thiadiazine 1,1-dioxide
 3-Cyclopentylamino-6,7-dimethyl-4H-thieno[2,3-e]-1,2,4-thiadiazine 1,1-dioxide
 5-Chloro-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
 15 5-Chloro-3-propylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
 5-Chloro-3-cyclopentylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
 5-Chloro-6-methyl-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
 6-chloro-3-isopropylamino-5-methyl-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
 6-chloro-3-cyclopentylamino-5-methyl-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
 20 6-Fluoro-3-propylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
 6-Fluoro-3-cyclopentylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
 5-Fluoro-3-propylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
 5-Fluoro-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide.
 3-Isopropylamino-7-methyl-4H-thieno[2,3-e]-1,2,4-thiadiazine 1,1-dioxide
 25 6-Chloro-3-cyclobutylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
 6-Chloro-3-(2-hydroxyethyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
 (±)-3-exo-Bicyclo[2.2.1]hept-2-ylamino-6-chloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
 dioxide
 (R)-6-Chloro-3-(2-hydroxypropyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
 30 6-Bromo-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
 5,6-Dibromo-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
 6-Chloro-3-cyclohexylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

- 6-Chloro-3-(furan-2-ylmethyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
6-Chloro-3-(1-ethylpropyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
6-Bromo-3-cyclopentylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
6-Chloro-3-(2-methylallyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide or
5 6-Cyano-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide.

The compounds of the present invention interact with the potassium channels and hence act as openers or blockers of the ATP-regulated potassium channels, which make them useful in the treatment of various diseases of the cardiovascular system, e.g. cerebral
10 ischemia, hypertension, ischemic heart diseases, angina pectoris and coronary heart diseases; the pulmonary system; the gastrointestinal system; the central nervous system and the endocrinological system.

Since some K_{ATP} -openers are able to antagonize vasospasms in basilar or cerebral
15 arteries the compounds of the present invention can be used for the treatment of vasospastic disorders such as subarachnoid haemorrhage and migraine.

The compounds of the present invention may also be used for the treatment of diseases associated with decreased skeletal muscle blood flow such as Raynauds disease and
20 intermittent claudication.

Further, the compounds of the invention may be used for the treatment of chronic airway diseases, including asthma, and for treatment of detrusor muscle instability secondary to bladder outflow obstruction and therefore for kidney stones by aiding their passage along
25 the urethra.

The present compounds could also be used for treatment of conditions associated with disturbances in gastrointestinal mobility such as irritable bowel syndrome. Additionally these compounds can be used for the treatment of premature labour and dysmenorrhea.
30

Potassium channel openers hyperpolarize neurons and inhibit neurotransmitter release and it is expected that such compounds can be used for the treatment of various diseases

of the central nervous system, e.g. epilepsy, ischemia and neurodegenerative diseases, and for the management of pain.

Further, potassium channel openers promote hairgrowth, therefore, the compounds of the
5 present invention can be used for the treatment of baldness.

Potassium channel openers also relax urinary bladder smooth muscle, thus, the compounds of the present invention can be used for the treatment of urinary incontinence.

- 10 In diseases such as nesidioblastosis and insulinoma in which a hypersecretion of insulin causes severe hypoglycemia the compounds of the present invention can be used to reduce insulin secretion. In obesity hyperinsulinemia and insulin resistance is very frequently encountered. This condition could lead to the development of noninsulin dependent diabetes (NIDDM). It is expected that potassium channel openers, and hence
15 the compounds of the present invention, can be used for reducing the hyperinsulinemia and thereby prevent diabetes and reduce obesity. In overt NIDDM treatment of hyperinsulinemia with potassium channel openers, and hence the present compounds, can be of benefit in restoring glucose sensitivity and normal insulin secretions.
- 20 In early cases of insulin dependent diabetes (IDDM) or in prediabetic cases, potassium channel openers and hence the present compounds can be used to induce pancreatic cell rest which may prevent the progression of the autoimmune disease.

The potassium channel openers of the present invention can be administered in
25 combination with an immunosuppressant or with an agent like nicotinamide, which will reduce autoimmune degeneration of beta-cells.

Combining beta-cell rest with a treatment protecting the beta-cells against cytokine mediated beta-cell impairment/cytotoxicity is another aspect of this invention.

- 30 Insulin requiring or Type 1 diabetes (IDDM) as well as late onset IDDM (also known as type 1.5. e.g. non-insulin-requiring Type 2 (NIIDM) patients with autoreactivity against beta-cell epitopes that later turns insulin requiring) have circulating autoreactive mono-

cytes/lymphocytes that homes to the islets/beta-cells and releases their cytokines. Some of these cytokines (e.g. interleukin-1b (IL-1b) , tumour necrosis factor a (TNFa) and interferon g (IFNg)) are specifically toxic to the beta-cells, e.g. through the induction of nitric oxide (NO) and other free radicals. Inhibition of this cytotoxicity, e.g. by co-
5 administering nicotinamide (NA), a derivative hereof or other cytokine protective compounds to the prediabetic/diabetic patients treated with the PCO compound is an example of this aspect. Nicotinamide belongs to the B-vitamin family and is derived from nicotinic acid by amidation of the carboxyl group. It processes none of nicotine's pharmacological properties. NA is converted into NAD⁺, which acts as a coenzyme for proteins involved in
10 tissue respiration. NA has been proposed to influence several of the putative intracellular molecular events following immune attack on the beta-cells. Animal experiments and early non-blinded experiments in humans have indicated a protective role of this compound against IDDM as well as in cytokine/immune mediated beta-cell destruction.

Yet another aspect of this application concerns the use of a PCO compound alone or in
15 combination with the inhibitor of cytokine/immune mediated beta-cell impairment , in transplantation, e.g. islet transplantation into diabetes patients. The use of one or both of these treatments may reduce the risk of rejection of the transplanted islets/beta-cells/engineered beta-cells/pancreas.

20 Compounds of the present invention which act as blockers of K_{ATP}-channels can be used for the treatment of NIDDM.

Preferably, the compounds of the present invention may be used for treatment or
25 prevention of diseases of the endocrinological system such as hyperinsulinaemia and diabetes.


Accordingly, in another aspect the invention relates to a compound of the general formula I or a pharmaceutically acceptable acid addition salt thereof for use as a therapeutically
30 acceptable substance, preferably for use as a therapeutically acceptable substance in the treatment of hyperinsulinaemia and treatment or prevention of diabetes.

22


Furthermore, the invention also relates to the use of the inventive compounds of formula I as medicaments useful for treating hyperinsulinaemia and treating or preventing diabetes.

In yet another aspect, the present invention relates to methods of preparing the above mentioned compounds. The methods comprises:

a) reacting a compound of formula II:



wherein A, B, D, R¹ and R⁴ are as defined above and Z is a leaving group such as alkoxy, alkylthio, halogen, preferentially chloro, bromo, iodo, trimethylamino, or methylsulfonyl with
15 a compound of formula III:




20

wherein R² and R³ are defined above to form a compound of the general formula I;

b) reacting a compound of formula IV:

25


23



wherein R^1 is hydrogen and A, B, D and X are as defined above, or B is NH and R^1 , A, D
 5 and X are as defined above, with the compound of formula III, or a suitable salt thereof in
 the presence of P_2O_5 and a high boiling tertiary amine or a suitable salt thereof, to form a
 compound of the general formula I;

c) reacting a compound of the formula IV:

10




15 wherein R^1 is hydrogen and A, B, D and X are as defined above or B is NH and R^1 , A, D
 and X are as defined above, with a compound of the formula III, or a suitable salt thereof
 in the presence of titanium tetrachloride and a solvent with which it may form a complex,
 like e.g. tetrahydrofuran, or a mixture of toluene and anisole, to form a compound of the
 general formula I;

20

d) reacting a compound of formula V

24



wherein R¹ and A are as defined above, with a compound of formula VI


5



wherein R³ is as defined above, to form a compound of the general formula I wherein D is
10 SO₂, B is >NR⁵, R² is H, and R⁴ and R⁵ together form a bond;

e) reacting a compound of the formula V

15



wherein R¹ and A are as defined above, with a compound of formula VII

20




wherein R³ is as defined, to form a compound of the general formula I wherein D is SO₂, B
is >NR⁵, R² is H, and R⁴ and R⁵ together form a bond;


25

f) reacting a compound of the formula V

25



5 wherein R¹ and A are defined as above, with a compound of formula VIII




10

wherein Y is NH or S, or a suitable salt thereof, to form a compound of the general formula I, wherein D is SO₂, B is >NR⁵, R⁴ and R⁵ together form a bond, and R² and R³ are H;

g) reacting in the presence of a base a compound of formula IX

15




20 or a suitable salt thereof, wherein R¹¹ is R¹ or EtOC(=O), wherein R¹ and A are defined as above, with a compound of formula X




wherein R^3 is as defined above, to form an adduct which may have either of the two structures XI or XII or be a mixture of the two

5




10



15

either of which by ring-closure, e.g. by treatment with phosgene in a suitable solvent, forms a compound of the general formula I, if R^{11} is R^1 , wherein D is $S(=O)_2$, B is $>NR^5$, R^2 is H, and R^4 and R^5 together form a bond, and a compound of the general formula XIII
 20 if R^{11} is $EtOC(=O)$;


27



(XIII)

h) hydrolyzing and subsequently decarboxylating a compound of the general formula XIII

5



(XIII)

10

to form a compound of the general formula I, wherein D is $S(=O)_2$, B is $>NR^5$, R^1 and R^2 are H, and R^4 and R^5 together form a bond, e.g. by heating the starting compound in aqueous base.

- 15 The starting materials are either known compounds or compounds which may be prepared in analogy with the preparation of known compounds or in analogy with known methods as described by e.g Huang B.-S., et al., *J. Med. Chem.*, **23**, 575-7 (1980), Ofitserov V. I. et al., *Khim. Geterotsikl. Soedin.*, 1119-22 (russ.) (1976), Topliss J. G., U.S. 3,641,017 (1972), Kotovskaya S. K. et al., *Khim.-Farm. Zh.*, **13**, 54-57 (russ.) (1979),
- 20 Meyer R. F., *J. Heterocycl. Chem.*, **6**, 407-408 (1969) and Hattori M., Yoneda M., and Goto M., *Bull. Chem. Soc. Jap.*, **46**, 1890-1 (1973), Williams T.R. and Cram D.J., *J. Org. Chem.*, **38**, 20-26 (1973), Barnes A.C., Kennewell P.D. and Taylor J.B., *J. Chem. Soc. Chem. Commun.*, 1973, 776-777, Stoss and Satzinger, *Chem. Ber.*, **109**, 2097 (1976),

Kresze G., Hatjiissaak A., Phosphorus Sulfur, 29, 41-47 (1987), Dillard R.D., Yen T.T., Stark P., Pavey D.E., J. Med. Chem., 23, 717-722 (1980).

PHARMACOLOGICAL METHODS

5

The ability of the compounds to interact with potassium channels can be determined by various methods. When patch-clamp techniques (Hamill O.P., Marty A., Neher E., Sakmann B. and Sigworth F.J., *Plügers Arch.*, 391, 85-100 (1981)) are used the ionic current through a single channel of a cell can be recorded.

10

The activity of the compounds as potassium channel openers can also be measured as relaxation of rat aorta rings according to the following procedure:

A section of rat thoracic aorta between the aortic arch and the diaphragm was dissected out and mounted as ring preparations as described by Taylor P.D. et al, *Brit J. Pharmacol*, 111, 42-48 (1994).

After a 45 min. equilibration period under a tension of 2 g, the preparations were contracted to achieve 80% of the maximum response using the required concentration of phenylephrine. When the phenylephrine response reached a plateau, potential vasodilatory agents were added cumulatively to the bath in small volumes using half log molar increments at 2 min intervals. Relaxation was expressed at the percentage of the contracted tension. The potency of a compound was expressed as the concentration required to evoke a 50% relaxation of the tissue.

25

Relaxation of rat aorta rings

Example	EC50 micro M
---------	--------------

4	2.8
---	-----

30 6	20.5
------	------

In the pancreatic b-cell the opening of the K_{ATP} -channels can be determined by measuring

the subsequent change in the concentration of cytoplasmic free Ca^{2+} concentration according to the method of Arkhammar P. et al. , *J. Biol. Chem.*, 262, 5448-5454 (1987).

$^{86}\text{Rb}^+$ efflux from a β -cell line

5

The RIN 5F cell line was grown in RPMI 1640 with Glutamax I, supplemented with 10 % fetal calf serum (from GibcoBRL, Scotland, UK) and maintained in an atmosphere of 5 % CO_2 / 95 % air at 37°C . The cells were detached with a Trypsin-EDTA solution (from GibcoBRL, Scotland, UK), resuspended in medium, added 1 mCi/ml $^{86}\text{Rb}^+$ and replated 10 into microtiter plates (96 well cluster 3596, sterile, from Costar Corporation, MA, USA) at a density of 50000 cells/well in 100 μl /well, and grown 24 hours before use in assay.

The plates were washed 4 times with Ringer buffer (150 mM NaCl, 10 mM Hepes, 3.0 mM KCl, 1.0 mM CaCl_2 , 20 mM Sucrose, pH 7.1). Eighty μl Ringer buffer and 1 μl control- or 15 test compound dissolved in DMSO was added. After incubation 1 h at room temperature with a lid, 50 μl of the supernatant was transferred to PicoPlates (Packard Instrument Company, CT, USA) and 100 μl MicroScint40 (Packard Instrument Company, CT, USA) added. The plates were counted in TopCount (Packard Instrument Company, CT, USA) for 1 min/well at the ^{32}P program.

20

The calculation of EC_{50} and E_{max} was done by SlideWrite (Advanced Graphics Software, Inc., CA, USA) using a four parameter logistic curve: $y = (a-d)/(1+(x/c)^b)+d$, where a = the activity estimated at concentration zero, b = a slope factor, c = the concentration at the middle of the curve and, d = the activity estimated at infinite concentration. $\text{EC}_{50} = c$ and 25 $\text{E}_{\text{max}} = d$, when the curve is turned of at infinite concentrations.

Increased Rb-efflux in rin 5F cells

Example EC50 micro M

30 4

5.5

6

31

The compounds according to the invention are effective over a wide dose range. In general satisfactory results are obtained with dosages from about 0.05 to about 1000 mg, preferably from about 0.1 to about 500 mg, per day. A most preferable dosage is about 1 mg to about 100 mg per day. The exact dosage will depend upon the mode of administration, form in which administered, the subject to be treated and the body weight of the subject to be treated, and the preference and experience of the physician or veterinarian in charge.

10

The route of administration may be any route, which effectively transports the active compound to the appropriate or desired site of action, such as oral or parenteral e.g. rectal, transdermal, subcutaneous, intravenous, intramuscular or intranasal, the oral route being preferred.

15

Typical compositions include a compound of formula I or a pharmaceutically acceptable acid addition salt thereof, associated with a pharmaceutically acceptable excipient which may be a carrier or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in form of a capsule, sachet, paper or other container. In making the compositions, conventional techniques for the preparation of pharmaceutical compositions may be used. For example, the active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a ampoule, capsule, sachet, paper, or other container. When the carrier serves as a diluent, it may be solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active compound. The active compound can be adsorbed on a granular solid container for example in a sachet. Some examples of suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, gelatine, lactose, amylose, magnesium stearate, talc, silicic acid, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxymethylcellulose and polyvinylpyrrolidone. The formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavouring agents. The formulations of the invention may be formulated so as to provide quick, sustained, or delayed release of the active

ingredient after administration to the patient by employing procedures well known in the art.

The pharmaceutical preparations can be sterilized and mixed, if desired, with auxiliary
5 agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or coloring substances and the like, which do not deleteriously react with the active compounds.

For parenteral application, particularly suitable are injectable solutions or suspensions, preferably aqueous solutions with the active compound dissolved in polyhydroxylated
10 castor oil.

Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application. Preferable carriers for tablets, dragees, or capsules include lactose, corn starch, and/or potato starch. A syrup or elixir can be used in
15 cases where a sweetened vehicle can be employed.

Generally, the compounds are dispensed in unit form comprising from about 1 to about 100 mg in a pharmaceutically acceptable carrier per unit dosage.

20 A typical tablet, appropriate for use in this method, may be prepared by conventional tableting techniques and contains:

Active compound	5.0 mg
Lactosum	67.8 mg Ph.Eur.
25 Avicel®	31.4 mg
Amberlite®	1.0 mg
Magnesii stearas	0.25 mg Ph.Eur.

EXAMPLES

30

The process of preparing the compounds of formula I is further illustrated in the following examples which, however, are not to be construed as limiting.

EXAMPLE 17-Cyano-3-isopropylamino-6-methyl-4H-thieno[2,3-e]-1,2,4-thiadiazine 1,1-dioxide

5

a) 4-Cyano-2-hydrazinocarbonyl-5-methyl-thiophene-3-sulfonamide

Methyl 4-cyano-5-methyl-3-sulfamoyl-thiophene-2-carboxylate (2.9 g), prepared from
10 methyl 3-amino-4-cyano-5-methyl-thiophene-2-carboxylate in analogy with known
procedures, e.g. F. Junquera et al. , Eur.J.Med.Chem. 23, 329 (1988), was suspended in
10 ml of ethanol. Hydrazine monohydrate (2 ml) was added and the mixture was stirred for
1 h at room temperature and then evaporated. The oily residue (3.3 g) was triturated with
10 ml of water and the precipitating crystals were collected by filtration, washed with water
15 and dried to give the title compound as yellow crystals (yield 1.62 g); m.p. 186-91 °C; ¹H-
NMR (DMSO-d₆), δ(ppm): 7.25 (br, 5H, NH/NH₂), 2.51 (s, 3H, CH₃).

b) 4-Cyano-5-methyl-3-sulfamoyl-thiophene-2-carbonyl azide

20

A solution of sodium nitrite (0.47 g) in 5 ml of water was added dropwise to a stirred
solution of 4-cyano-2-hydrazinocarbonyl-5-methyl-thiophene-3-sulfonamide (1.6 g) in 38
ml of 1 M hydrochloric acid at 0 °C. The resulting mixture was stirred for 30 min at 0 °C
and then filtered. The filter cake was washed with water and dried in vacuum to give 1.35
25 g of the title compound; ¹H-NMR (DMSO-d₆), δ(ppm): 7.75 (br, 1H, NH₂), 2.75 (s, 1H,
CH₃).

c) 4-Cyano-2-ethoxycarbonylamino-5-methyl-thiophene-3-sulfonamide

30

4-cyano-5-methyl-3-sulfamoyl-thiophene-2-carbonyl azide (1.35 g) was added in small
portions over 5 min to 50 ml of abs. ethanol at reflux temperature. The resulting solution

was refluxed for 5 min and then evaporated. The residue crystallized when triturated with 20 ml of ethyl acetate. The crystals were filtered off, rinsed with ethyl acetate and dried to give the title compound; ¹H-NMR (DMSO-d₆), δ(ppm): 9.45 (s, 1H, NH), 7.82 (br, 2H, NH₂), 4.23 (q, 2H, CH₂), 2.51 (s, 3H, CH₃), 1.25 (t, 3H, CH₃).

5

d) N-(4-Cyano-2-ethoxycarbonylamino-5-methyl-3-thienylsulfonyl)-N'-isopropylthiourea

A mixture of 4-cyano-2-ethoxycarbonylamino-5-methyl-thiophene-3-sulfonamide (0.50 g), potassium carbonate (0.36 g) and isopropyl isothiocyanate (300 μl) in 10 ml of dry acetone
10 was heated at 55 °C for 18 h and then evaporated to dryness. The residue was dissolved in 10 ml of water, and pH was adjusted to 2 by dropwise addition of 1M hydrochloric acid. The precipitate was filtered off, rinsed with a small amount of water and dried to give 0.34 g of the title compound; m.p. 169-171 °C.

15

e) Ethyl 7-cyano-3-isopropylamino-6-methyl-4H-thieno[2,3-e]-1,2,4-thiadiazine-4-carboxylate 1,1-dioxide

To a stirred solution of N-(4-cyano-2-ethoxycarbonylamino-5-methyl-3-thienylsulfonyl)-N'-
20 isopropylthiourea (0.3 g) and triethylamine (320 μl) in 10 ml of dry THF at 0 °C was added 750 μl of a 20% solution of phosgene in toluene. The mixture was stirred at 0 °C for 1 h and then evaporated to dryness. The residue was triturated with 10 ml of water, filtered off, rinsed on the filter with water and dried to give 0.24 g of crude title compound; m.p. 116-119 °C. The product was used for the next step without purification.

25

f) 7-Cyano-3-isopropylamino-6-methyl-4H-thieno[2,3-e]-1,2,4-thiadiazine 1,1-dioxide

A mixture of ethyl 7-cyano-3-isopropylamino-6-methyl-4H-thieno[2,3-e]-1,2,4-thiadiazine-
30 4-carboxylate 1,1-dioxide (0.15 g) and 5 ml of 1 M aqueous sodium hydroxide was stirred at room temperature for 1 h. Then the mixture was filtered and pH was adjusted to 1-2 by dropwise addition of 4M hydrochloric acid. After stirring for 30 min the precipitate was

filtered off, rinsed with a small amount of water and dried to give the title compound; m.p. 235-238 °C; ¹H-NMR (DMSO-d₆), δ(ppm): 11.35 (s, 1H, NH), 7.55 (br d, 1H, NH), 3.98 - 3.77 (m, 1H, CH), 2.50 (s, 1H, CH₃), 1.15 (d, 6H, CH₃).

5

EXAMPLE 2

7-Cyano-6-methyl-3-propylamino-4H-thieno[2,3-e]-1,2,4-thiadiazine 1,1-dioxide

10

a) N-(4-Cyano-2-ethoxycarbonylamino-5-methyl-3-thienylsulfonyl)-N'-propylthiourea

The title compound was prepared from 4-cyano-2-ethoxycarbonylamino-5-methylthiophene-3-sulfonamide and propyl isothiocyanate in analogy with the synthesis described in Example 1-d; m.p. 167-168 °C.

15

b) Ethyl 7-cyano-6-methyl-3-propylamino-4H-thieno[2,3-e]-1,2,4-thiadiazine-4-carboxylate 1,1-dioxide

20 The title compound was prepared by ring closure of N-(4-cyano-2-ethoxycarbonylamino-5-methyl-3-thienylsulfonyl)-N'-propylthiourea in analogy with the synthesis described in Example 1-e; m.p. 175-179 °C.

25 c) 7-Cyano-6-methyl-3-propylamino-4H-thieno[2,3-e]-1,2,4-thiadiazine 1,1-dioxide

The title compound was prepared by hydrolysis and subsequent decarboxylation of ethyl 7-cyano-6-methyl-3-propylamino-4H-thieno[2,3-e]-1,2,4-thiadiazine-4-carboxylate 1,1-dioxide in analogy with the synthesis described in Example 1-f; m.p. 293-98 °C; ¹H-NMR (DMSO-d₆), δ(ppm): 11.6 (s, 1H, NH), 7.65 (br, 1H, NH), 3.14 (dd, 2H, CH₂), 2.58 (s, 1H, CH₃), 1.65 - 1.4 (m, 2H, CH₂), 0.89 (t, 3H, CH₃).

30

EXAMPLE 36-Chloro-3-(3-methylbutyl)amino-4H-thieno[3.2-e]-1.2.4-thiadiazine 1.1-dioxide

5

a) N-(3-Amino-5-chloro-2-thienylsulfonyl)-N'-(3-methylbutyl)thiourea

Potassium *tert*-butoxide (0.49 g, 4.4 mmol) was added to a solution of 3-amino-5-chlorothiophene-2-sulfonamide hydrochloride (0.5 g, 2.0 mmol) in dry *N,N*-dimethylformamide (5 ml) with stirring on an ice bath. After 10 min, 3-methylbutyl isothiocyanate (0.31 g, 2.4 mmol) was added dropwise to the resulting suspension, and the mixture was stirred for 3.5 h at 0 to 20 °C. Most of the solvent was evaporated at 40°C, and the residue was taken up in 25 ml of water, treated with decolourising charcoal, and filtered. Acidification of the filtrate with acetic acid to pH 3-4 and filtration afforded 0.21 g (29%) of the title compound; mp 114-115°C decomp., ¹H-NMR (DMSO-*d*₆): δ 0.85 (d, 6H, 2 X CH₃), 1.40 (q, 2H, CH₂), 1.50 (m, 1H, CH), 3.45 (q, 2H, CH₂), 6.45 (br, 2H, NH₂), 6.65 (s, 1H, H-4), 8.30 (br t, 1H, NH), 11.3 (br s, 1H).

15

b) 6-Chloro-3-(3-methylbutyl)amino-4H-thieno[3.2-e]-1.2.4-thiadiazine 1.1-dioxide

20

Phosgene (0.242 ml, 20 % in toluene) was added dropwise to a solution of *N*-(3-amino-5-chloro-2-thienylsulfonyl)-*N'*-(3-methylbutyl)thiourea (0.153 g, 0.42 mmol) and dry triethylamine (0.118 ml, 0.85 mmol) in dry tetrahydrofuran (3 ml) with stirring at 0°C. The mixture was stirred for 2 h at 0°C, and evaporated to dryness. Crystallisation was obtained from ethyl acetate, and the precipitate was isolated by filtration, washed with water and dried affording 38 mg (27%) of the title compound. mp 230-231.5°C, ¹H-NMR (DMSO-*d*₆): δ 0.90 (d, 6H, 2 X CH₃), 1.40 (q, 2H, CH₂), 1.60 (m, 1H, CH), 3.20 (q, 2H, CH₂), 7.05 (s, 1H, H-5), 7.25 (br s, 1H, NH), 10.95 (s, 1H, NH). MS: M/e 307(M⁺)

25

30

EXAMPLE 4

6-Chloro-3-(1-methylheptyl)amino-4H-thieno[3.2-e]-1.2.4-thiadiazine 1.1-dioxidea) N-(3-Amino-5-chloro-2-thienylsulfonyl)-N'-(1-methylheptyl)thiourea

5

The title compound was prepared from 3-amino-5-chlorothiophene-2-sulfonamide hydrochloride and 1-methylheptyl isothiocyanate by a procedure analogous to the procedure described in example 3-a; a syrup was obtained (yield 29%), ¹H-NMR (DMSO-d₆): δ 0.90 (t, 3H, CH₃), 1.10 (d, 3H, CH₃), 1.25 (m, 8H), 1.47 (m, 2H, CH₂), 4.25 (p, 1H, 10 CH), 6.5 (br s, 2H, NH₂), 6.65 (s, 1H, H-4), 7.95 (br , 1H, NH), 11.2 (br s, 1H).

b) 6-Chloro-3-(1-methylheptyl)amino-4H-thieno[3.2-e]-1.2.4-thiadiazine 1.1-dioxide

The title compound was prepared from N-(3-amino-5-chloro-2-thienylsulfonyl)-N'-(1-15 methylheptyl)thiourea by a procedure analogous to the procedure described in example 3-b (yield 71%); mp 179-181°C, ¹H-NMR (DMSO-d₆): δ 0.85 (t, 3H, CH₃), 1.15 (d, 3H, CH₃), 1.30 (m, 8H), 1.45 (m, 2H, CH₂), 3.75 (p, 1H, CH), 7.05 (s, 1H, H-5), 7.10 (br s, 1H, NH), 10.65 (s, 1H, NH). MS: M/e 349 (M⁺).

20

EXAMPLE 56-Chloro-3-(1-ethylpentyl)amino-4H-thieno[3.2-e]-1.2.4-thiadiazine 1.1-dioxide25 a) N-(3-Amino-5-chloro-2-thienylsulfonyl)-N'-(1-ethylpentyl)thiourea

The title compound was prepared from 3-amino-5-chlorothiophene-2-sulfonamide hydrochloride and 1-ethylpentyl isothiocyanate by a procedure analogous to the procedure described in example 3-a; a syrup was obtained (yield 36%), ¹H-NMR (DMSO-d₆): δ 0.8 (2 30 q, 6H, 2 x CH₃), 1.2 (m, 4H), 1.5 (m, 4H), 4.20 (sextet, 1H, CH), 6.55 (br , 2H, NH₂), 6.65 (s, 1H, H-4), 7.85 (br d , 1H, NH), 11.3 (br s, 1H, NH).

b) 6-Chloro-3-(1-ethylpentyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

The title compound was prepared from *N*-(3-amino-5-chloro-2-thienylsulfonyl)-*N'*-(1-ethylpentyl)thiourea by a procedure analogous to the procedure described in example 3-b (yield 35%); mp 165-167.5°C, ¹H-NMR (DMSO-d₆): δ 0.85 (2 q, 6H, 2 x CH₃), 1.25 (m, 4H), 1.45 (m, 4H), 3.65 (m, 1H, CH), 7.0 (br, 1H, NH), 7.05 (s, 1H, H-5), 10.65 (br s, 1H, NH). MS: M/e 335 (M+).

10

EXAMPLE 6

6-Chloro-3-(2-methylbutyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

a) *N*-(3-Amino-5-chloro-2-thienylsulfonyl)-*N'*-(2-methylbutyl)thiourea

15

The title compound was prepared from 3-amino-5-chlorothiophene-2-sulfonamide hydrochloride and 2-methylbutyl isothiocyanate by a procedure analogous to the procedure described in example 3-a (yield 28%); mp 116.5-118 °C, ¹H-NMR (DMSO-d₆): δ 0.8 (2 d, 6H, 2 x CH₃), 1.10 (m, 1H), 1.30 (m, 1H), 1.65 (m, 1H), 3.40 (m, 2H + HDO, CH₂), 6.45 (br, 2H, NH₂), 6.65 (s, 1H, H-4), 8.25 (br t, 1H, NH), 11.3 (br s, 1H).

20

b) 6-Chloro-3-(2-methylbutyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

The title compound was prepared from *N*-(3-amino-5-chloro-2-thienylsulfonyl)-*N'*-(2-methylbutyl)thiourea by a procedure analogous to the procedure described in example 3-b (yield 49%); mp 232-234 °C, ¹H-NMR (DMSO-d₆): δ 0.85 (2 d, 6H, 2 x CH₃), 1.15 (m, 1H), 1.40 (m, 1H), 1.60 (m, 1H), 3.10 (m, 2H, CH₂), 7.05 (s, 1H, H-5), 7.25 (br, 1H, NH), 10.85 (br s, 1H, NH). MS: M/e 307 (M+).

Analysis: calc. For C₁₀H₁₄ClN₃O₂S₂ C 39.02 H 4.58 N 13.65, found C 38.98 H 4.72 N 13.40

30

EXAMPLE 76-Chloro-3-(1-methylhexyl)amino-4H-thieno[3.2-e]-1.2.4-thiadiazine 1.1-dioxide

5

a) *N*-(3-Amino-5-chloro-2-thienylsulfonyl)-*N'*-(1-methylhexyl)thiourea

The title compound was prepared from 3-amino-5-chlorothiophene-2-sulfonamide hydrochloride and 1-methylhexyl isothiocyanate by a procedure analogous to the procedure described in example 3-a; a syrup was obtained (yield 43%), ¹H-NMR (DMSO-d₆): δ 0.85 (t, 3H, CH₃), 1.10 (d, 3H, CH₃), 1.25 (m, 6H), 1.45 (m, 2H), 4.25 (m, 1H, CH), 6.50 (br, 2H, NH₂), 6.65 (s, 1H, H-4), 7.93 (br, 1H, NH), 11.3 (br s, 1H, NH).

b) 6-Chloro-3-(1-methylhexyl)amino-4H-thieno[3.2-e]-1.2.4-thiadiazine 1.1-dioxide

15

The title compound was prepared from *N*-(3-amino-5-chloro-2-thienylsulfonyl)-*N'*-(1-methylhexyl)thiourea by a procedure analogous to the procedure described in example 3-b (yield 63%); mp 158-162 °C, ¹H-NMR (DMSO-d₆): δ 0.85 (t, 3H, CH₃), 1.15 (d, 3H, CH₃), 1.25 (m, 6H), 1.45 (m, 2H), 3.75 (m, 1H, CH), 7.05 (s, 1H, H-5), 7.15 (br s, 1H, NH), 10.75 (br s, 1H, NH). MS: M/e 335 (M⁺).

EXAMPLE 825 6-Chloro-3-(cyclopentyl)amino-4H-thieno[3.2-e]-1.2.4-thiadiazine 1.1-dioxidea) *N*-(3-Amino-5-chloro-2-thienylsulfonyl)-*N'*-cyclopentylthiourea

The title compound was prepared from 3-amino-5-chlorothiophene-2-sulfonamide hydrochloride and cyclopentyl isothiocyanate by a procedure analogous to the procedure described in example 3-a (yield 46%); ¹H-NMR (DMSO-d₆): δ 1.30 - 1.70 (m, 6H), 1.90 (m, 2H), 4.40 (sextet, 1H, CH), 6.55 (br, 2H, NH₂), 6.65 (s, 1H, H-4), 8.15 (br d, 1H, NH), 11.2

(br s, 1H, NH).

b) 6-Chloro-3-(cyclopentyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

- 5 The title compound was prepared from *N*-(3-amino-5-chloro-2-thienylsulfonyl)-*N'*-cyclopentylthiourea by a procedure analogous to the procedure described in example 3-b (yield 57%); mp 291-292 °C, ¹H-NMR (DMSO-*d*₆): δ 1.40 - 1.70 (m, 6H, CH₃), 1.90 (m, 2H), 3.95 (sextet, 1H, CH), 7.05 (s, 1H, H-5), 7.3 (br, 1H, NH), 10.70 (br s, 1H, NH). MS: M/e 305 (M⁺).

10

EXAMPLE 9

6-Chloro-3-(cyclohexylmethyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

15

a) *N*-(3-Amino-5-chloro-2-thienylsulfonyl)-*N'*-cyclohexylmethylthiourea

The title compound was prepared from 3-amino-5-chlorothiophene-2-sulfonamide hydrochloride and cyclohexylmethyl isothiocyanate by a procedure analogous to the
20 procedure described in example 3-a; a syrup was obtained (yield 8%), ¹H-NMR (DMSO-*d*₆): δ 0.95 (m, 2H), 1.25 (m, 3H), 1.70 (m, 6H), 3.45 (d, 2H, CH₂), 4.45 (br, HDO + NH), 6.65 (s, 1H, H-4).

6-Chloro-3-(cyclohexylmethyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

25

The title compound was prepared from *N*-(3-amino-5-chloro-2-thienylsulfonyl)-*N'*-cyclohexylmethylthiourea by a procedure analogous to the procedure described in example 3-b (yield 68%); mp > 200 °C decomp., ¹H-NMR (DMSO-*d*₆): δ 0.90 (m, 2H), 1.15 (m, 3H), 1.70 (m, 6H), 3.05 (t, 2H, CH₂), 7.05 (s, 1H, H-5), 7.25 (br, 1H, NH), 10.95
30 (br s, 1H, NH). MS: M/e 333 (M⁺).

EXAMPLE 10Ethyl 3-(6-chloro-1,4-dihydro-1,1-dioxothieno[3,2-e]-1 λ^6 ,2,4-thiadiazin-3-ylamino)butanoate

5

a) Ethyl 3-{3[(3-amino-5-chlorothiophen-2-yl)sulfonyl]thioureido}butanoate

The title compound was prepared from 3-amino-5-chlorothiophene-2-sulfonamide hydrochloride and ethyl 3-isothiocyanatobutyrate by a procedure analogous to the
10 procedure described in example 3-a (yield 93%); ¹H-NMR (DMSO-d₆): δ 1.18 (d, 3H, CH₃), 1.20 (t, 3H, CH₃), 2.61 (m, 2H, CH₂), 4.08 (q, 2H, CH₂), 4.58 (m, 1H, CH), 6.46 (br s, 2H, NH₂), 6.65 (s, 1H, H-4), 8.34 (br d, 1H, NH), 11.35 (br s, 1H).

b) Ethyl 3-(6-chloro-1,4-dihydro-1,1-dioxothieno[3,2-e]-1 λ^6 ,2,4-thiadiazin-3-ylamino)butanoate
15

The title compound was prepared from ethyl 3-{3[(3-amino-5-chlorothiophen-2-yl)sulfonyl]thioureido}butanoate by a procedure analogous to the procedure described in example 3-b except that the product was purified by column chromatography (yield 71%);
20 mp 151-155°C (ethyl acetate); ¹H-NMR (DMSO-d₆): δ 1.18 (t, 3H, CH₃), 1.20 (d, 3H, CH₃), 2.57 (m, 2H, CH₂), 4.07 (q, 2H, CH₂), 4.17 (m, 1H, CH), 7.05 (s, 1H, H-5), 7.25 (br, 1H, NH), 10.99 (s, 1H, NH); MS: m/e 351/353 (M⁺); (C₁₁H₁₄N₃ClO₄S₂ · 0.2 ethyl acetate) calc. C 38.36 H 4.26 N 11.37, found C 38.35 H 4.18 N 11.58.

25

EXAMPLE 113-(6-Chloro-1,4-dihydro-1,1-dioxothieno[3,2-e]-1 λ^6 ,2,4-thiadiazin-3-ylamino)butanoic acid

30 Ethyl 3-(6-chloro-1,4-dihydro-1,1-dioxothieno[3,2-e]-1 λ^6 ,2,4-thiadiazin-3-ylamino)butanoate (0.5 g, 1.42 mmol) was hydrolyzed to the acid by stirring in 5 ml of 2 N sodium hydroxide for 2 h at room temperature. The solution was treated with decolorising charcoal, filtered and acidified with 4 M hydrochloric acid to pH 2. The resulting precipitate

was isolated by filtration, washed with water and dried to give 294 mg (64 %) of the title compound; m.p. 218-223°C; ¹H-NMR (DMSO-d₆): δ 1.19 (d, 3H, CH₃), 2.49 (m, 2H, CH₂), 4.10 (m, 1H, CH), 7.06 (s, 1H, H-5), 7.25 (br, 1H, NH), 10.99 (s, 1H, NH), 12.38 (br s, 1H, OH); MS: m/e 305/307 (M - H₂O)⁺; (C₉H₁₀N₃ClO₄S₂) calc. C 33.39 H 3.11 N 12.98, found C 33.62 H 3.11 N 12.81.

EXAMPLE 12

10 6-Chloro-3-(3-hydroxy-1-methylpropyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

Toluene (5 ml) was cooled to 10°C and lithium aluminum hydride (114 mg, 3 mmol) was added followed by 0.53 ml of tetrahydrofuran. Ethyl 3-(6-chloro-1,4-dihydro-1,1-
15 dioxothieno[3,2-e]-1λ⁶,2,4-thiadiazin-3-ylamino)butanoate (352 mg, 1 mmol) was added to the cooled solution and the mixture was stirred for 2 h at 0°C and then at room temperature over night. The mixture was cooled on an ice bath and 10 ml of water was added dropwise followed by 5-10 ml of 20 % sulfuric acid. The mixture was extracted with ether (3 x 30 ml) and the organic phase was washed with water, dried and evaporated to
20 dryness. The crude product was mixed with the solid that was formed in the aqueous phase and finally purified by column chromatography on silica with ethyl acetate/methanol (9:1) affording 120 mg (39 %) of the title compound; m.p. 199-203°C; ¹H-NMR (DMSO-d₆): δ 1.14 (d, 3H, CH₃), 1.65 (m, 2H, CH₂), 3.48 (m, 2H, CH₂), 3.90 (m, 1H, CH), 4.60 (br s, 1H, OH), 7.06 (s, 1H, H-5), 7.17 (br, 1H, NH), 10.86 (s, 1H, NH); MS: m/e 309/311 (M⁺);
25 (C₉H₁₂N₃ClO₃S₂ · 0.15 ethyl acetate) calc. C 35.70 H 4.12 N 13.01, found C 35.7 H 4.1 N 13.1.

EXAMPLE 13

(R)-6-Chloro-3-(1-phenylethyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

a) (R)-N-(3-Amino-5-chloro-2-thienylsulfonyl)-N'-(1-phenylethyl)thiourea

The title compound was prepared from 3-amino-5-chlorothiophene-2-sulfonamide hydrochloride and D- α -methylbenzyl isothiocyanate by a procedure analogous to the procedure described in example 3-a (yield 96% impure product); $^1\text{H-NMR}$ (DMSO-d_6): δ 1.46 (d, 3H, CH_3), 5.36 (quint, 1H, CH), 6.45 (br s, 2H, NH_2), 6.64 (s, 1H, H-4), 7.2-7.4 (m, 5H, ArH), 8.53 (br d, 1H, NH), 11.3 (br s, 1H).

b) (R)-6-Chloro-3-(1-phenylethyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

10

The title compound was prepared from crude (R)-N-(3-Amino-5-chloro-2-thienylsulfonyl)-N'-(1-phenylethyl)thiourea by a procedure analogous to the procedure described in example 3-b except that the product was purified by column chromatography on silica with dichloromethane/methanol (19:1), (yield 17%); mp 218-220°C (ethyl acetate); $^1\text{H-NMR}$ (DMSO-d_6): δ 1.48 (d, 3H, CH_3), 4.97 (quint, 1H, CH), 7.10 (s, 1H, H-5), 7.2-7.4 (m, 5H, ArH), 7.73 (br, 1H, NH), 10.81 (s, 1H, NH); MS: m/e 341/343 (M^+); ($\text{C}_{13}\text{H}_{12}\text{N}_3\text{Cl}_1\text{O}_2\text{S}_2$) calc. C 45.68 H 3.54 N 12.29, found C 45.83 H 3.55 N 12.04.

20

EXAMPLE 14(S)-3-sec-Butylamino-6-chloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

- 25 A solution of 3,6-dichloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide (257 mg, 1.0 mmol) and (S)-(+)-sec-butylamine (0.31 ml, 3.0 mmol) was stirred in 10 ml of abs ethanol for 4 days at 80°C in a sealed flask. The cooled solution was concentrated *in vacuo* and the residue was stirred with water (10 ml) followed by adjustment to pH 2 with 4M hydrochloric acid. The initially formed gummy product was crystallized by stirring at 0°C.
- 30 The precipitate was isolated by filtration, washed with water, and recrystallised from ethyl acetate/methanol followed by drying *in vacuo* at 30°C over night to give 181 mg (62 %) of the pure title compound; mp 228-230°C (ethyl acetate); $^1\text{H-NMR}$ (DMSO-d_6): δ 0.88 (t,

3H, CH₃), 1.14 (d, 3H, CH₃), 1.49 (m, 2H, CH₂), 3.68 (m, 1H, CH), 7.08 (s, 1H, H-5), 7.13 (br, 1H, NH), 10.73 (br s, 1H, NH); MS: m/e 293/295 (M⁺); (C₉H₁₂N₃Cl₁O₂S₂) calc. C 36.79 H 4.12 N 14.30, found C 36.9 H 4.1 N 14.2.

5

EXAMPLE 15

6-Chloro-3-isopropylamino-4H-thieno[2.3-e]-1.2.4-thiadiazine 1.1-dioxide

10

a) N-[5-Chloro-3-(isopropylthiocarbamoyl)sulfamoylthiophen-2-yl]acetamide

Potassium *tert*-butoxide (135 mg, 1.2 mmol) was added to a solution of N-(5-chloro-3-sulfamoylthiophen-2-yl)-acetamide (255 mg, 1.0 mmol) in dry *N,N*-dimethylformamide (5 ml) with stirring on an ice bath. After 5 min, isopropyl isothiocyanate (0.128 ml, 1.2 mmol) was added dropwise and the solution was stirred for 30 min at 0°C and then at room temperature for 3 h. A further amount of potassium *tert*-butoxide (135 mg, 1.2 mmol) was added to the solution and stirring was continued at room temperature for 1 h. The solvent was evaporated at <50°C, and the residue was taken up in 10 ml of water and the aqueous solution was adjusted to pH 2 with 4 M hydrochloric acid. The resulting precipitate was isolated by filtration, washed with water and dried to give 274 mg (77%) of crude title compound; ¹H-NMR (DMSO-d₆): δ 1.12 (d, 6H, 2 x CH₃), 2.28 (s, 3H, COCH₃), 4.21 (m, 1H, NCH), 7.15 (s, 1H, H-4), 8.34 (br d, 1H, NH), 10.26 (s, 1H, NH).

25 b) 6-Chloro-3-isopropylamino-4H-thieno[2.3-e]-1.2.4-thiadiazine 1.1-dioxide

Phosgene (0.416 ml, 20 % in toluene) was added dropwise to a solution of N-[5-chloro-3-(isopropylthiocarbamoyl)sulfamoylthiophen-2-yl]acetamide (261 mg, 0.73 mmol) and dry triethylamine (0.209 ml, 1.5 mmol) in dry tetrahydrofuran (5 ml) with stirring at 0°C. The mixture was stirred for 1 h at 0°C, and evaporated to dryness. The residue was triturated with 10 ml of water, and the precipitate was isolated by filtration, washed with water and finally deacetylated by stirring in 2 ml of 2 N sodium hydroxide for 90 min at room temperature. The solution was acidified to pH 2 with 4 M hydrochloric acid and the

44

precipitate was filtered off and recrystallised from ethyl acetate with decolorising charcoal affording 44 mg (21%) of the pure title compound; mp 272-274°C (ethyl acetate); ¹H-NMR (DMSO-d₆): δ 1.16 (d, 6H, 2 x CH₃), 3.85 (m, 1H, NCH), 7.23 (s, 1H, H-7), 7.48 (br d, 1H, NH), 11.12 (s, 1H, NH); MS: m/e 279/281 (M⁺).

5

EXAMPLE 16

6-Chloro-3-cyclopentylamino-4H-thieno[2.3-e]-1.2.4-thiadiazine 1.1-dioxide

10

a) N-[5-Chloro-3-(cyclopentylthiocarbamoyl)sulfamoylthiophen-2-yl]acetamide

The title compound was prepared from N-(5-chloro-3-sulfamoylthiophen-2-yl)-acetamide and cyclopentyl isothiocyanate by a procedure analogous to the procedure described in example 15 a (yield of crude product: 93%); ¹H-NMR (DMSO-d₆): δ 1.3-2.0 (m, 8H, (CH₂)₄), 2.28 (s, 3H, CH₃), 4.32 (sext, 1H, CH), 7.16 (s, 1H, H-4), 8.48 (br d, 1H, NH), 10.23 (br s, 1H, NH).

b) 6-Chloro-3-cyclopentylamino-4H-thieno[2.3-e]-1.2.4-thiadiazine 1.1-dioxide

20

The title compound was prepared from N-[5-chloro-3-(cyclopentylthiocarbamoyl)sulfamoylthiophen-2-yl]acetamide by a procedure analogous to the procedure described in example 15 b (yield 32%); mp 280-282°C (aqueous ethanol); ¹H-NMR (DMSO-d₆): δ 1.4-2.0 (m, 8H, (CH₂)₄), 3.96 (sext, 1H, CH), 7.23 (s, 1H, H-7), 7.62 (br, 1H, NH), 11.09 (s, 1H, NH); MS: m/e 305/307 (M⁺).

EXAMPLE 17

30

6-Bromo-3-isopropylamino-4H-thieno[3.2-e]-1.2.4-thiadiazine 1.1-dioxide

Bromine (0.12 ml, 2.3 mmol) was added dropwise to a solution of 6-chloro-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide (280 mg, 1.0 mmol) in 10 ml of acetic acid and the mixture was stirred for 24 h at 100°C in a sealed flask. The cooled mixture was evaporated to dryness and the residue was triturated with water to give a solid, which was recrystallised from ethanol/water (1:1) affording 118 mg (39 %) of the title compound contaminated with 10 % of the starting material; mp ca. 279°C (aqueous ethanol); ¹H-NMR (DMSO-d₆): δ 1.16 (d, 6H, 2 x CH₃), 3.86 (m, 1H, CH), 7.14 (s, 1H, H-5), 7.18 (br, 1H, NH), 10.74 (s, 1H, NH); MS: m/e 323/325 (M⁺).

10

EXAMPLE 18

3-Isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

15

Powdered potassium hydroxide (128 mg, 2.28 mmol) was added to a solution of 6-chloro-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide (319 mg, 1.14 mmol) in 25 ml of methanol and the mixture was hydrogenated at room temperature and atmospheric pressure for 3 days with 150 mg of 10 % palladium on carbon. The catalyst was removed by filtration and washed with ethanol and water. The combined filtrate was acidified with 4 M hydrochloric acid and evaporated to dryness. The residue was recrystallised from water/ethanol and finally from ethyl acetate with decolorising charcoal affording the title compound contaminated with starting material, which could be removed by silica gel column chromatography; ¹H-NMR (DMSO-d₆): δ 1.16 (d, 6H, 2 x CH₃), 3.88 (m, 1H, CH), 6.95 (d, 1H, H-5), 7.03 (br d, 1H, NH), 7.88 (d, 1H, H-6), 10.70 (br s, 1H).

EXAMPLE 19

3-Isopropylamino-7-methyl-4H-thieno[2,3-e]-1,2,4-thiadiazine 1,1-dioxide

30

a) Cyanomethanesulfonamide

Dry THF (200 ml) was saturated with ammonia at -10 °C. Then a solution of cyanomethane-sulfonyl chloride (13.9 g; prepared according to Sammes et al, J.Chem.Soc., 1971, 2151-5155) in 10 ml of dry THF was added in small portions with stirring over 20 min at -10 °C. After the addition the temperature was raised to 0 °C and the reaction mixture was filtered. Removal of the solvent from the filtrate and purification of the residue by column chromatography on silica gel eluted with ethyl acetate gave the title compound as beige crystals; m.p. 97-99 °C; IR (KBr), ν (cm⁻¹): 3316, 3328 (N-H), 2266 (C≡N), 1371, 1151 (SO₂).

10

b) 2-Amino-4-methyl-thiophene-3-sulfonamide

A mixture of cyanomethanesulfonamide (1.0 g), 2,5-dihydroxy-2,5-dimethyl-1,4-dithiane (0.75 g), and triethylamine (100 μ l) in absolute ethanol (7 ml) was heated at 45-50 °C under nitrogen for 3 h. Then the solvent was evaporated and the residue partitioned in water (30 ml) and ethyl acetate (50 ml). The aqueous phase was extracted with 4 x 50 ml of ethyl acetate. The combined ethyl acetate phases were dried over sodium sulfate and evaporated. The residue was purified by column chromatography on silica gel eluted with ethyl acetate. The title compound was obtained as a yellow solid, yield 0.65 (41%); m.p. 142-144 °C; ¹H-NMR (CD₃OD), δ (ppm): 7.19 (s, 1 H, C(5)H), 4.88 (br, 4 H, SO₂NH₂ + H₂O), 4.71 (s, 2 H, NH₂), 2.41 (s, 3 H, CH₃); MS: 192 (M⁺), 112 (M⁺ - SO₂NH₂), 72 (CH₃-C₂HS⁺).

25

c) N-(2-Amino-4-methyl-3-thienylsulfonyl)-N'-isopropylthiourea

A mixture of 2-amino-4-methyl-thiophene-3-sulfonamide (0.30 g), potassium carbonate (0.32 g), and isopropyl isothiocyanate (272 μ l) in dry acetone (5 ml) under nitrogen was heated at 50-55 °C overnight. Then the solvent was evaporated and the residue was dissolved in water (15 ml); pH was adjusted to 2 by addition of 4 M hydrochloric acid, and the mixture was stirred for 30 min. The precipitated crystals were filtered off, rinsed with a

small amount of water and dried to give 0.24 g (yield 54%) of the title compound; m.p. 118-120 °C.

d) 3-Isopropylamino-7-methyl-4H-thieno[2,3-e]-1,2,4-thiadiazine 1,1-dioxide

5

A 20 % solution of phosgene in toluene (715 µl) was added to a stirred and cooled solution of N-(2-amino-4-methyl-3-thienylsulfonyl)-N'-isopropylthiourea (0.22 g) and triethylamine (313 µl) in dry THF (5 ml) the temperature being kept below 5 °C. After stirring for 1.5 h the mixture was evaporated and triturated with 10 ml of water. The precipitate was
10 collected by filtration and dried to give 0.14 g of crude product. The crystals were heated at 70 °C with 5 ml of ethyl acetate and the resulting mixture was cooled to 0 °C for 10 min and then filtered. The filter cake was rinsed with a minute amount of ethyl acetate and dried to give 0.087 g (yield 45 %) of the title compound as tan crystals; m.p. 152-154 °C; ¹H-NMR (DMSO-d₆): δ (ppm): 7.10 (br d, 1 H, NH), 6.61 (s, 1 H, N(4)H), 6.52 (s, 1 H,
15 C(6)H), 3.89 (m, 1 H, CH), 2.32 (s, 3 H, CH₃), 1.18 (d, 6 H, CH₃).

EXAMPLE 20

6-Chloro-3-cyclobutylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

20

A solution of 3,6-dichloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide (257 mg, 1.0 mmol) in cyclobutylamine (1.0 ml) was stirred for 18 h at 90°C in a sealed flask. The cooled solution was concentrated *in vacuo* and the residue was stirred with water (10 ml) at 0°C followed by adjustment to pH 2 with 4M hydrochloric acid. The product was isolated
25 by filtration, washed with water, and recrystallised from methanol/ethyl acetate followed by drying *in vacuo* at room temperature to give 155 mg (53 %) of the pure title compound; mp 315-317°C dec.; ¹H-NMR (DMSO-d₆): δ 1.58-1.75 (m, 2H), 1.89-2.05 (m, 2H), 2.19-2.30 (m, 2H), 4.16 (m, 1H), 7.06 (s, 1H), 7.62 (br s, 1H), 10.83 (br s, 1H); MS: m/e 291/293 (M⁺); (C₉H₁₀N₃ClO₂S₂) calc C 37.05 H 3.45 N 14.40, found C 37.18 H 3.48 N 14.19.

30

EXAMPLE 21

6-Chloro-3-(2-hydroxyethyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

A solution of 3,6-dichloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide (206 mg, 0.8 mmol) in ethanolamine (1.0 ml) was stirred for 18 h at 100°C in a sealed flask. The cooled solution was concentrated *in vacuo* and the residue was stirred with water (5 ml) at 0°C followed by adjustment to pH 2 with 4M hydrochloric acid. The product was isolated by filtration, washed with water, and recrystallised from ethanol/water to give 135 mg (60 %) of the pure title compound; mp 260-261°C dec.; ¹H-NMR (DMSO-d₆): δ 3.26 (distorted q, 2H), 3.50 (t, 2H), 4.85 (br s, 1H), 7.07 (s, 1H), 7.20 (br s, 1H), 10.9 (br s, 1H); MS: m/e 281/283 (M⁺); (C₇H₈N₃Cl₂O₃S₂) calc C 29.84 H 2.86 N 14.91, found C 30.13 H 2.84 N 14.79.

10

EXAMPLE 22

(±)-3-exo-Bicyclo[2.2.1]hept-2-ylamino-6-chloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

15

A solution of 3,6-dichloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide (206 mg, 0.8 mmol) in exo-2-aminonorbomane (1.0 ml) was stirred for 20 h at 100°C in a sealed flask. The mixture was stirred with water (10 ml) at 0°C followed by adjustment to pH 2 with 4M hydrochloric acid. The product was isolated by filtration, washed with water, and recrystallised from ethyl acetate/methanol to give 168 mg (63 %) of the pure title compound; mp 323-324°C dec.; ¹H-NMR (DMSO-d₆): δ 1.05-1.55 (m, 7H), 1.68-1.77 (m, 1H), 2.18-2.28 (m, 2H), 3.51 (m, 1H), 7.09 (s, 1H), 7.2 (br s, 1H), ca. 10.5 (br s, 1H); MS: m/e 331/333 (M⁺); (C₁₂H₁₄N₃Cl₂O₃S₂) calc C 43.43 H 4.25 N 12.66, found C 43.67 H 4.26 N 12.55.

25

EXAMPLE 23

(R)-6-Chloro-3-(2-hydroxypropyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

30 A solution of 3,6-dichloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide (200 mg, 0.78 mmol) in (R)-(-)-1-amino-2-propanol (1.0 ml) was stirred for 18 h at 100°C in a sealed flask. The cooled solution was stirred with water (3 ml) at 0°C followed by adjustment to pH 2 with 4M hydrochloric acid. The product was isolated by filtration, washed with water, and dried *in vacuo* at room temperature to give 170 mg (74 %) of the pure title compound;

mp 210-211°C.; ¹H-NMR (DMSO-d₆): δ 1.08 (d, 3H), 3.0-3.1 (m, 1H), 3.15-3.25 (m, 1H), 3.72-3.82 (m, 1H), 4.91 (br s, 1H), 7.09 (s, 1H), 7.14 (br s, 1H), 10.95 (br s, 1H).; MS: m/e 297/295(M⁺); (C₈H₁₀N₃ClO₃S₂· 0.5 H₂O) calc C 31.53 H 3.64 N 13.79, found C 31.57 H 3.58 N 13.58.

5

EXAMPLE 24

6-Bromo-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

- 10 Bromine (1.26 ml, 25 mmol) was added dropwise to a solution of 6-chloro-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide (2.3 g, 8.2 mmol) in 25 ml of acetic acid and the mixture was stirred for 48 h at 100°C in a sealed flask. The cooled mixture was evaporated to dryness and the residue which consisted of two major products was triturated with water to give a solid, which was recrystallised from ethyl acetate/methanol with decolorising charcoal to afford 538 mg (20 %) of the title compound. An
- 15 analytically pure sample was obtained by preparative hplc on a Source RPC 15 column using acetonitrile/water (20:80) with 0.1% TFA as eluent; mp 282-283°C; ¹H-NMR (DMSO-d₆): δ 1.16 (d, 6H), 3.86 (m, 1H), 7.14 (s, 1H), 7.18 (br, 1H), 10.74 (s, 1H); MS: m/e 323/325 (M⁺); (C₈H₁₀N₃BrO₂S₂); calc C 29.64 H 3.11 N 12.96; found C 29.49 H 3.04 N 12.59.
- 20

EXAMPLE 25

5,6-Dibromo-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

- The mother liquor from the crystallisation of 6-bromo-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide described above was evaporated to dryness and the residue was purified by chromatography on silica with dichloromethane/methanol (95:5). Recrystallisation from ethyl acetate gave 270 mg (8%) of pure title compound; mp 250-251°C; ¹H-NMR (DMSO-d₆): δ 1.18 (d, 6H), 3.86 (m, 1H), 7.18 (br, 1H), 10.31 (s, 1H); MS: m/e 405/403/401 (M⁺); (C₈H₉N₃Br₂O₂S₂); calc C 23.84 H 2.25 N 10.42; found C 24.14 H 2.18 N 10.25.
- 30

35

EXAMPLE 26

6-Chloro-3-cyclohexylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

a) N-(3-Amino-5-chloro-2-thienylsulfonyl)-N'-(cyclohexyl)thiourea

The title compound was prepared from 3-amino-5-chlorothiophene-2-sulfonamide

5 hydrochloride and cyclohexyl isothiocyanate by a procedure analogous to the procedure described in example 3-a (yield 78%); ¹H-NMR (DMSO-d₆): δ 1.1-1.9 (m, 10H), 4.0 (m, 1H), 6.45 (br s, 2H), 6.66 (s, 1H), 8.05 (br d, 1H), 11.2 (br s, 1H).

b) 6-Chloro-3-cyclohexylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

10

The title compound was prepared from N-(3-Amino-5-chloro-2-thienylsulfonyl)-N'-(cyclohexyl)thiourea by a procedure analogous to the procedure described in example 3-b (yield 66%); mp 282-284°C (ethyl acetate/methanol); ¹H-NMR (DMSO-d₆): δ 1.1-1.9 (m, 10H), 3.55 (m, 1H), 7.08 (s, 1H), 7.19 (br, 1H), 10.73 (br s, 1H); MS: m/e 321/319 (M⁺);

15 (C₁₁H₁₄N₃ClO₂S₂) calc. C 41.31 H 4.41 N 13.14, found C 41.66 H 4.45 N 12.99.

EXAMPLE 276-Chloro-3-(furan-2-ylmethyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

20

a) N-(3-Amino-5-chloro-2-thienylsulfonyl)-N'-(furan-2-ylmethyl)thiourea

The title compound was prepared from 3-amino-5-chlorothiophene-2-sulfonamide hydrochloride and furfuryl isothiocyanate by a procedure analogous to the procedure

25 described in example 3-a (yield of crude product: 92%).

b) 6-Chloro-3-(furan-2-ylmethyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

The title compound was prepared from crude N-(3-Amino-5-chloro-2-thienylsulfonyl)-N'-(furan-2-ylmethyl)thiourea by a procedure analogous to the procedure described in example 3-b except that the product was purified by column chromatography on silica with dichloromethane/methanol (19:1), (yield 11%); mp 224-225°C; ¹H-NMR (DMSO-d₆): δ 4.41 (d, 2H), 6.33 (m, 1H), 6.41 (m, 1H), 7.05 (s, 1H), 7.62 (br s, 1H), 7.75 (br t, 1H), 11.2 (br s, 1H); (C₁₀H₈N₃ClO₃S₂); calc C 37.80 H 2.54 N 13.22; found C 37.87 H 2.51 N 13.10).

35

EXAMPLE 28

6-Cyano-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

To a solution of 6-bromo-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide (243 mg, 0.75 mmol) in dry N,N-dimethylformamide (2 ml) was added
5 copper(I) cyanide (135 mg, 1.5 mmol) and the mixture was heated at 150° C for 2 h under nitrogen. The dark mixture was allowed to cool to room temperature and water was added. The suspension was made basic by the addition of 1 N sodium hydroxide, filtered and the filtrate was acidified by the addition of 4 M hydrochloric acid. The resulting precipitate was purified by preparative hplc on a Source RPC 15 column
10 using acetonitrile/water (20:80) with 0.1% TFA as eluent to afford 4 mg (2%) of the pure title compound; LC-MS: m/e 271 ((M + 1)⁺).

EXAMPLE 29

15

6-Bromo-3-cyclopentylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

Bromine (0.12 ml, 2.3 mmol) was added dropwise to a solution of 6-chloro-3-cyclopentylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine (305 mg, 1.0 mmol) in acetic acid
20 (10 ml) and the mixture was stirred for 21 h at 100 °C in a sealed flask. The cooled mixture was evaporated to dryness and the residue was triturated with water to give a solid, which was recrystallised from ethyl acetate and ethanol affording the title compound (166 mg, 47%) contaminated with 33% of the starting material. Purification by preparative HPLC gave the title compound (65 mg, 18%) contaminated with
25 3% of the starting material. ¹H-NMR (DMSO): δ 10.7 (s, 1H, NH); 7.35 (br s, 1H, NH); 7.13 (s, 1H, H-7); 4.00 (sextet, 1H); 1.9 (m, 2H); 1.7 to 1.4 ppm (m, 6H).
Decomp.: 287-294 °C

30

EXAMPLE 306-Chloro-3-(2-methylallyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide


A solution of 3,6-dichloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide (128 mg, 0.5

mmol) in methallylamine (0.5 ml) was stirred for 48 h at 90°C in a sealed flask. The cooled solution was concentrated *in vacuo* and the residue was stirred with water (3 ml) followed by adjustment to pH 2 with 4M hydrochloric acid. The product was isolated by filtration and washed with water, to give 92 mg (64 %) of the pure title 5 compound; mp 224-226 °C (dec.); ¹H-NMR (DMSO-d₆): δ 1.72 (s, 3H), 3.75 (d, 2H), 4.83 (s, 2H), 7.05 (s, 1H), 7.45 (br s, 1H), 11.0 (br s, 1H).

CLAIMS

1. A compound of the general formula I

5



10 wherein

B represents $>NR^5$ or $>CR^5R^6$, wherein R^5 and R^6 independently are hydrogen; hydroxy; C_{1-6} -alkoxy; or C_{1-6} -alkyl, C_{3-6} -cycloalkyl, C_{2-6} -alkenyl or C_{2-6} -alkynyl optionally mono- or polysubstituted with halogen; or R^5 and R^6 together represent one of the bonds in a double bond between the atoms 2 and 3 of formula I;

15

D represents $-S(=O)_2-$ or $-S(=O)-$; or

D-B represents $-S(=O)(R^7)=N-$

20 wherein R^7 is C_{1-6} -alkyl; or aryl or heteroaryl optionally mono- or polysubstituted with halogen, hydroxy, C_{1-6} -alkoxy, aryloxy, arylalkoxy, nitro, amino, C_{1-6} -monoalkyl- or dialkylamino, cyano, acyl, or C_{1-6} -alkoxycarbonyl;

R^1 is hydrogen; hydroxy; C_{1-6} -alkoxy; or C_{1-6} -alkyl, C_{3-6} -cycloalkyl, C_{2-6} -alkenyl or C_{2-6} -alkynyl optionally mono- or polysubstituted with halogen and R^4 is hydrogen; or R^4 together with R^5 represent one of the bonds in a double bond between the atoms 2 and 3 of formula I; or R^1 together with R^4 represent one of the bonds in a double bond between the atoms 3 and 4 of formula I;

R² is hydrogen; hydroxy; C₁₋₆-alkoxy; or C₁₋₆-alkyl, C₃₋₆-cycloalkyl, C₂₋₆-alkenyl or C₂₋₆-alkynyl optionally mono- or polysubstituted with halogen;


5 R³ is R⁸; -OR⁸; -C(=X)R⁸; -NR⁸R⁹; bicycloalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl optionally mono- or polysubstituted with halogen, hydroxy, C₁₋₆-alkoxy, aryloxy, arylalkoxy, nitro, amino, C₁₋₆-monoalkyl- or dialkylamino, cyano, oxo, acyl or C₁₋₆-alkoxycarbonyl; or aryl substituted with C₁₋₆-alkyl;

10 wherein R⁸ is hydrogen; C₃₋₆-cycloalkyl or (C₃₋₆-cycloalkyl)C₁₋₆-alkyl, the C₃₋₆-cycloalkyl group optionally being mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; a 3-6 membered saturated ring system comprising one or more nitrogen-, oxygen- or sulfur atoms; or straight or branched C₁₋₁₈-alkyl optionally mono- or polysubstituted with halogen, hydroxy, C₁₋₆-alkoxy, C₁₋₆-alkylthio, C₃₋₆-cycloalkyl, aryl, aryloxy, arylalkoxy, nitro,
15 amino, C₁₋₆-monoalkyl- or dialkylamino, cyano, oxo, formyl, acyl, carboxy, C₁₋₆-alkoxy-carbonyl, or carbamoyl;

X is O or S;

20 R⁹ is hydrogen; C₁₋₆-alkyl; C₂₋₆-alkenyl; C₃₋₆-cycloalkyl optionally mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; or

R⁸ and R⁹ together with the nitrogen atom form a 3-12 membered mono- or bicyclic system, in which one or more of the carbon atoms may be exchanged with nitrogen,
25 oxygen or sulfur, each of these ring systems optionally being mono- or polysubstituted with halogen, C₁₋₆-alkyl, hydroxy, C₁₋₆-alkoxy, C₁₋₆-alkoxy-C₁₋₆-alkyl, nitro, amino, cyano, trifluoromethyl, C₁₋₆-monoalkyl- or dialkylamino, oxo; or R³ is



wherein n,m,p independently are 0,1,2,3 and R¹⁰ is hydrogen; hydroxy; C₁₋₆-alkoxy; C₃₋₆-
 5 cycloalkyl optionally mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-
 alkoxy; C₁₋₆-alkyl, C₂₋₆-alkenyl or C₂₋₆-alkynyl optionally mono- or polysubstituted with
 halogen; or

R² and R³ together with the nitrogen atom forms a 3-12 membered mono- or bicyclic
 10 system, in which one or more of the carbon atoms may be exchanged with nitrogen,
 oxygen or sulfur, each of these ring systems optionally being mono- or polysubstituted
 with halogen, C₁₋₆-alkyl, hydroxy, C₁₋₆-alkoxy, C₁₋₆-alkoxy-C₁₋₆-alkyl, nitro, amino, cyano,
 trifluoromethyl, C₁₋₆-monoalkyl- or dialkylamino or oxo;

15 A together with carbon atoms 5 and 6 of formula I represents a 5 or 6 membered hetero-
 cyclic system comprising one or more nitrogen-, oxygen- or sulfur atoms, the heterocyclic
 systems optionally being mono- or polysubstituted with halogen; C₁₋₁₂-alkyl; C₃₋₆-cycloalkyl;
 hydroxy; C₁₋₆-alkoxy; C₁₋₆-alkoxy-C₁₋₆-alkyl; nitro; amino; cyano; cyanomethyl; perhalome-
 thyl; C₁₋₆-monoalkyl- or dialkylamino; sulfamoyl; C₁₋₆-alkylthio; C₁₋₆-alkylsulfonyl; C₁₋₆-
 20 alkylsulfinyl; C₁₋₆-alkylcarbonylamino; arylthio, arylsulfinyl, arylsulfonyl, the aryl group
 optionally being mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy;
 C₁₋₆-alkoxycarbonyl; C₁₋₆-alkoxycarbonyl-C₁₋₆-alkyl; carbamyl; carbamyl- methyl; C₁₋₆-
 monoalkyl- or dialkylaminocarbonyl; C₁₋₆-monoalkyl- or dialkylaminothiocarbonyl; ureido;
 C₁₋₆-monoalkyl- or dialkylaminocarbonylamino, thioureido; C₁₋₆-monoalkyl- or dialkylami-
 25 nothiocarbonyl- amino; C₁₋₆-monoalkyl- or dialkylaminosulfonyl; carboxy; carboxy-C₁₋₆-
 alkyl; acyl; aryl, arylalkyl, aryloxy, the aryl group optionally being mono- or polysubstituted
 with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; (1,2,4-oxadiazol-5-yl)- or (1,2,4-oxadiazol-
 3-yl)-C₁₋₆-alkyl the oxadiazolyl group optionally being substituted with C₁₋₆-alkyl or C₃₋₆-

cycloalkyl; or a 5 - 6 membered nitrogen containing ring, optionally substituted with phenyl or C₁₋₆-alkyl;

provided that A together with carbon atoms 5 and 6 of formula I do not form a pyridine ring and that the following compounds 3-aminoimidazo[4,5-e]-1,2,4-thiadiazine 1,1-dioxide and 3- (benzoylamino)imidazo[4,5-e]-1,2,4-thiadiazine 1,1-dioxide are not included;

or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form.

10

2. A compound according to claim 1, wherein R² is hydrogen or C₁₋₆-alkyl.

3. A compound according to claim 1 or 2 wherein R³ is R⁸, -OR⁸, NR⁸R⁹ or aryl, the aryl groups optionally being substituted with C₁₋₆-alkyl; wherein

15

R⁸ is hydrogen; C₃₋₆-cycloalkyl; (C₃₋₆-cycloalkyl)C₁₋₆-alkyl; a 3 - 6 membered saturated ring system comprising one, two or three nitrogen-, oxygen- or sulfur atoms; or straight or branched C₁₋₁₈-alkyl optionally substituted with halogen, hydroxy, C₁₋₆-alkoxy, C₁₋₆-alkylthio, C₃₋₆-cycloalkyl or aryl,

20

R⁹ is hydrogen, C₁₋₆-alkyl or C₃₋₆-cycloalkyl; or

R⁸ and R⁹ together with the nitrogen atom form a 4 - 6 membered ring.

25 4. A compound according to any one of the preceding claims wherein R³ is secondary C₃₋₆-alkyl, tertiary C₄₋₆-alkyl, C₃₋₆-cycloalkyl or (C₃₋₆-cycloalkyl)methyl.

5. A compound according to any one of the preceding claims wherein A together with carbon atoms 5 and 6 of formula I forms a 5 membered heterocyclic system
30 containing one hetero atom selected from nitrogen and sulfur, the heterocyclic system optionally being mono- or disubstituted with halogen; C₁₋₁₂-alkyl; C₃₋₆-cycloalkyl; cyano; cyanomethyl; perhalomethyl; sulfamoyl; C₁₋₆-alkylthio; C₁₋₆-alkylsulfonyl; C₁₋₆-alkylsulfinyl;

arylthio, arylsulfinyl, arylsulfonyl, the aryl group optionally being mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; C₁₋₆-alkoxycarbonyl-C₁₋₆-alkyl; carbamylmethyl; carboxy-C₁₋₆-alkyl; aryloxy; (1,2,4-oxadiazol-5-yl)- or (1,2,4-oxadiazol-3-yl)C₁₋₆-alkyl, the oxadiazolyl group optionally being substituted with C₁₋₆-alkyl or C₃₋₆-cycloalkyl; acyl or a 5 - 6 membered nitrogen containing ring, optionally substituted with phenyl or C₁₋₆-alkyl.


6. A compound according to any one of the preceding claims wherein A together with carbon atoms 5 and 6 of formula I forms a 5 membered heterocyclic system containing two hetero atoms selected from nitrogen, oxygen and sulfur, the heterocyclic system optionally being substituted with halogen; C₁₋₁₂-alkyl; C₃₋₆-cycloalkyl; cyano; cyanomethyl; perhalomethyl; sulfamoyl; C₁₋₆-alkylsulfonyl; C₁₋₆-alkylsulfinyl; arylthio, arylsulfinyl, arylsulfonyl, the aryl group optionally being mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; C₁₋₆-alkoxycarbonyl-C₁₋₆-alkyl; carbamylmethyl; carboxy-C₁₋₆-alkyl; aryloxy; (1,2,4-oxadiazol-5-yl)- or (1,2,4-oxadiazol-3-yl)C₁₋₆-alkyl, the oxadiazolyl group optionally being substituted with C₁₋₆-alkyl or C₃₋₆-cycloalkyl; acyl; or a 5 - 6 membered nitrogen containing ring, optionally substituted with phenyl or C₁₋₆-alkyl.

7. A compound according to any one of the preceding claims wherein A together with carbon atoms 5 and 6 of formula I forms a 6 membered aromatic heterocyclic system containing two or three nitrogen atoms, the heterocyclic system optionally being substituted with halogen; C₁₋₁₂-alkyl; C₃₋₆-cycloalkyl; cyano; cyanomethyl; perhalomethyl; sulfamoyl; C₁₋₆-alkylthio; C₁₋₆-alkylsulfonyl; C₁₋₆-alkylsulfinyl; arylthio, arylsulfinyl, arylsulfonyl, the aryl group optionally being mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; C₁₋₆-alkoxycarbonyl-C₁₋₆-alkyl; carbamylmethyl; carboxy-C₁₋₆-alkyl; aryloxy; (1,2,4-oxadiazol-5-yl)- or (1,2,4-oxadiazol-3-yl)C₁₋₆-alkyl, the oxadiazolyl group optionally being substituted with C₁₋₆-alkyl or C₃₋₆-cycloalkyl; acyl; or a 5 - 6 membered nitrogen containing ring, optionally substituted with phenyl or C₁₋₆-alkyl.

8. A compound according to any one of the preceding claims wherein A together with carbon atoms 5 and 6 of formula I forms a 6 membered non-aromatic heterocyclic system containing one or two hetero atoms selected from nitrogen, oxygen and sulfur, the

heterocyclic system optionally being substituted with halogen; C₁₋₁₂-alkyl; C₃₋₆-cycloalkyl; cyano; cyanomethyl; perhalomethyl; sulfamoyl; C₁₋₆-alkylthio; C₁₋₆-alkylsulfonyl; C₁₋₆-alkylsulfinyl; arylthio, arylsulfinyl, arylsulfonyl, the aryl group optionally being mono- or polysubstituted with C₁₋₆-alkyl, halogen, hydroxy or C₁₋₆-alkoxy; C₁₋₆-alkoxycarbonyl-C₁₋₆-alkyl; carbamylmethyl; carboxy-C₁₋₆-alkyl; aryloxy; (1,2,4-oxadiazol-5-yl)- or (1,2,4-oxadiazol-3-yl)-C₁₋₆-alkyl, the oxadiazolyl group optionally being substituted with C₁₋₆-alkyl or C₃₋₆-cycloalkyl; acyl; or a 5 - 6 membered nitrogen containing ring, optionally substituted with phenyl or C₁₋₆-alkyl.

- 10 9. A compound according to any one of the claims 1 - 8, wherein the general formula I is



15

wherein

R¹ and R⁵ independently are hydrogen; hydroxy; C₁₋₆-alkoxy; or C₁₋₆-alkyl, C₃₋₆-cycloalkyl, C₂₋₆-alkenyl or C₂₋₆-alkynyl optionally mono- or polysubstituted with halogen and R⁴ is
 20 hydrogen; or

R⁴ together with R⁵ represent one of the bonds in a double bond between the atoms 2 and 3 of formula I and R¹ is as defined above; or

25 R⁴ together with R¹ represent one of the bonds in a double bond between the atoms 3 and 4 of formula I and R⁵ is as defined above;

D represents -S(=O)₂- or S(=O)-; and

D represents $-S(=O)R^7=$

wherein R^7 is C_{1-6} -alkyl; or aryl or heteroaryl optionally mono- or polysubstituted with
 5 halogen, hydroxy, C_{1-6} -alkoxy, aryloxy, arylalkoxy, nitro, amino, C_{1-6} -monoalkyl- or
 dialkylamino, cyano, acyl or C_{1-6} -alkoxycarbonyl; and

A, R^2 and R^3 are as defined above.


10 15. A compound according to claim 14 wherein R^1 is hydrogen or C_{1-6} -alkyl.

16. A compound according to claim 14 or 15 wherein R^1 together with R^4 represent
 one of the bonds in a double bond between the atoms 3 and 4 of formula I.

15 17. A compound according to any one of the claims 14 - 16 wherein R^7 is C_{1-6} -alkyl,
 phenyl or pyridyl.

18. A compound according to any one of the claims 1 - 8 wherein the general formula
 I is

20



25 wherein

R^1 , R^5 and R^6 independently are hydrogen; hydroxy; C_{1-6} -alkoxy; or C_{1-6} -alkyl, C_{3-6} -
 cycloalkyl, C_{2-6} -alkenyl or C_{2-6} -alkynyl optionally mono- or polysubstituted with halogen and
 R^4 is hydrogen; or

R⁴ together with R⁵ represent one of the bonds in a double bond between the atoms 2 and 3 of formula I and R¹ and R⁶ are as defined above; or

5 R⁴ together with R¹ represent one of the bonds in a double bond between the atoms 3 and 4 of formula I and R⁵ and R⁶ are as defined above;

D represents -S(=O)₂- or -S(=O)-; and

10 A, R², R³ are as defined above.

19. A compound according to claim 18 wherein R¹, R⁵ and R⁶ independently are hydrogen or C₁₋₆-alkyl.

15 20. A compound according claim 18 or 19 wherein R¹ together with R⁴ represent one of the bonds in a double bond between the atoms 3 and 4 of formula I.

21. A compound according to any one of the claims 18 - 20 wherein R⁴ together with R⁵ represent one of the bonds in a double bond between the atoms 2 and 3 of formula I.

20

22. A compound according to any one of the claims 18 - 21 wherein D is -S(=O)₂-.

23. A compound selected from the following:

25 7-Cyano-3-isopropylamino-6-methyl-4H-thieno[2,3-e]-1,2,4-thiadiazine 1,1-dioxide

7-Cyano-6-methyl-3-propylamino-4H-thieno[2,3-e]-1,2,4-thiadiazine 1,1-dioxide

6-Chloro-3-isopentylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

6-Chloro-3-(1-methylheptyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

6-Chloro-3-(1-ethylpentyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

30 6-Chloro-3-(2-methylbutyl)amino- 4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

6-Chloro-3-(1-methylhexyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

6-Chloro-3-cyclopentylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide

- 6-Chloro-3-cyclohexylmethylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
Ethyl 3-(6-chloro-1,4-dihydro-1,1-dioxothieno[3,2-e]-1 λ^6 ,2,4-thiadiazin-3-ylamino)butanoate
3-(6-Chloro-1,4-dihydro-1,1-dioxothieno[3,2-e]-1 λ^6 ,2,4-thiadiazin-3-ylamino)butanoic acid
5 6-Chloro-3-(3-hydroxy-1-methylpropyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
(R)-6-Chloro-3-(1-phenylethyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
(S)-3-sec-Butylamino-6-chloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
6-Chloro-3-isopropylamino-4H-thieno[2,3-e]-1,2,4-thiadiazine 1,1-dioxide
10 6-Chloro-3-cyclopentylamino-4H-thieno[2,3-e]-1,2,4-thiadiazine 1,1-dioxide
6-Bromo-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
3-Isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
6-Fluoro-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
3-Cyclobutylamino-5,6-dimethyl-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
15 3-Cyclopentylamino-5,6-dimethyl-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
3-Isopropylamino-6,7-dimethyl-4H-thieno[2,3-e]-1,2,4-thiadiazine 1,1-dioxide
3-Cyclobutylamino-6,7-dimethyl-4H-thieno[2,3-e]-1,2,4-thiadiazine 1,1-dioxide
3-Cyclopentylamino-6,7-dimethyl-4H-thieno[2,3-e]-1,2,4-thiadiazine 1,1-dioxide
5-Chloro-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
20 5-Chloro-3-propylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
5-Chloro-3-cyclopentylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
5-Chloro-6-methyl-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
6-chloro-3-isopropylamino-5-methyl-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
6-chloro-3-cyclopentylamino-5-methyl-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
25 6-Fluoro-3-propylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
6-Fluoro-3-cyclopentylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
5-Fluoro-3-propylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide or
5-Fluoro-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide.
3-Isopropylamino-7-methyl-4H-thieno[2,3-e]-1,2,4-thiadiazine 1,1-dioxide
30 6-Chloro-3-cyclobutylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
6-Chloro-3-(2-hydroxyethyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
(\pm)-3-exo-Bicyclo[2.2.1]hept-2-ylamino-6-chloro-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-


dioxide

- (R)-6-Chloro-3-(2-hydroxypropyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
 6-Bromo-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
 5,6-Dibromo-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
 5 6-Chloro-3-cyclohexylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
 6-Chloro-3-(furan-2-ylmethyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
 6-Chloro-3-(1-ethylpropyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
 6-Bromo-3-cyclopentylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide
 6-Chloro-3-(2-methylallyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide or
 10 6-Cyano-3-isopropylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide.

24. Compounds according to any one of the preceding claims which acts as openers of the K_{ATP} -regulated potassium channels.

15

25. A method of preparing a compound of formula I, characterized in
 a) reacting a compound of formula II:




20

(II)

wherein A, B, D, R^1 and R^4 are as defined above and Z is a leaving group such as alkoxy, alkylthio, halogen, preferentially chloro, bromo, iodo, trimethylamino, or methylsulfonyl with
 25 a compound of formula III:


64



wherein R^2 and R^3 are defined above to form a compound of the general formula I;

5

b) reacting a compound of formula IV:




10

wherein R^1 is hydrogen and A, B, D and X are as defined above, or B is NH and R^1 , A, D and X are as defined above, with the compound of formula III, or a suitable salt thereof in the presence of P_2O_5 and a high boiling tertiary amine or a suitable salt thereof, to form a

15 compound of the general formula I;

c) reacting a compound of the formula IV:




20

65

wherein R^1 is hydrogen and A, B, D and X are as defined above or B is NH and R^1 , A, D and X are as defined above, with a compound of the formula III, or a suitable salt thereof in the presence of titanium tetrachloride and a solvent with which it may form a complex, like e.g. tetrahydrofuran, or a mixture of toluene and anisole, to form a compound of the general formula I;

d) reacting a compound of formula V

10



wherein R^1 and A are as defined above, with a compound of formula VI

15




wherein R^3 is as defined above, to form a compound of the general formula I wherein D is SO_2 , B is $>NR^5$, R^2 is H, and R^4 and R^5 together form a bond;

20

e) reacting a compound of the formula V

25



66

wherein R^1 and A are as defined above, with a compound of formula VII




5


wherein R^3 is as defined, to form a compound of the general formula I wherein D is SO_2 , B is $>NR^5$, R^2 is H, and R^4 and R^5 together form a bond;

f) reacting a compound of the formula V

10



15 wherein R^1 and A are defined as above, with a compound of formula VIII




20

wherein Y is NH or S, or a suitable salt thereof, to form a compound of the general formula I, wherein D is SO_2 , B is $>NR^5$, R^4 and R^5 together form a bond, and R^2 and R^3 are H;


g) reacting in the presence of a base a compound of formula IX

25

67




or a suitable salt thereof, wherein R^{11} is R^1 or $\text{EtOC}(=\text{O})$, wherein R^1 and A are defined as
 5 above, with a compound of formula X




wherein R^3 is as defined above, to form an adduct which may have either of the two
 10 structures XI or XII or be a mixture of the two


15



20



either of which by ring-closure, e.g. by treatment with phosgene in a suitable solvent,
 5 forms a compound of the general formula I, if R^{11} is R^1 , wherein D is $S(=O)_2$, B is $>NR^5$,
 R^2 is H, and R^4 and R^5 together form a bond, and a compound of the general formula XIII
 if R^{11} is $EtOC(=O)$;




10

(XIII)

h) hydrolyzing and subsequently decarboxylating a compound of the general formula XIII

15



(XIII)

20 to form a compound of the general formula I, wherein D is $S(=O)_2$, B is $>NR^5$, R^1 and R^2
 are H, and R^4 and R^5 together form a bond, e.g. by heating the starting compound in
 aqueous base.

26. A pharmaceutical composition comprising a compound according to any of the claim 1 - 24 or a or a pharmaceutical acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a
5 racemic mixture, or any tautomeric form together with one or more pharmaceutically acceptable carriers or diluents.
27. A pharmaceutical composition for use in the treatment of diseases of the endocrinological system such as hyperinsulinaemia and diabetes comprising a compound
10 according to any of the claims 1 - 24 or a pharmaceutical acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form together with one or more pharmaceutically acceptable carriers or diluents.
- 15 28. The pharmaceutical composition according to claim 26 or 27 in the form of an oral dosage unit or parenteral dosage unit.
29. A pharmaceutical composition according to claim 26 or 27 wherein said compound is administered as a dose in a range from about 0.05 to 1000, preferably from
20 about 0.1 to 500 and especially in the range from 50 to 200 mg per day.
30. A compound according to any one of the claims 1 - 24 or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form
25 for therapeutical use.
31. A compound according to any one of the claims 1 - 24 or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form
30 for therapeutical use in the treatment or prevention of diseases of the endocrinological system, such as hyperinsulinaemia and diabetes.

32. The use of a compound according to any one of the claims 1 - 24 or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form as a medicament.

5

33. The use of a compound according to any of the claims 1 - 24 for preparing a medicament.

34. The use of a compound according to any one of the claims 1 - 24 or a
10 pharmaceutically acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form for the preparation of a medicament for the treatment or prevention of diseases of the endocrinological system, such as hyperinsulinaemia and diabetes.

15 35. A method of treating or preventing diseases of the endocrinological system, such as hyperinsulinaemia and diabetes in a subject in need thereof comprising administering an effective amount of a compound according to any of the claims 1 - 24 to said subject.

36. A process for the manufacture of a medicament, particular to be used in the
20 treatment or prevention of diseases of the endocrinological system, such as hyperinsulinaemia and diabetes which process comprising bringing a compound of formula I according to any of the claims 1 - 24 or a pharmaceutically acceptable salt thereof into a galenic dosage form.

25 37. Any novel feature or combination of features as described herein.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 98/00288

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C07D 513/04, A61K 31/54

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CA, WPI

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 9726265 A1 (NOVO NORDISK A/S), 24 July 1997 (24.07.97)	1-37
	--	
X	J. Med. Chem., Volume 23, 1980, Bao-Shan Huang et al, "Synthesis and Properties of the Sulfonyl Analogues of 4(5)-Amino imidazole-5(4)-carboxamide, 4(5)-(Formylamino)imidazole-5(4)-carboxamide, Guanine, and Xanthine" page 575 - page 577	1-31,36,37
	--	
X	J. Med. Chem., Volume 36, 1993, Bernard Pirotte et al, "3-(Alkylamino)-4H-pyrido(4,3-e)-1,2,4-thiadiazine 1,1-Dioxides as, Powerful Inhibitors of Insulin Release from Rat Pancreatic B-Cells: A New Class of Potassium Channel Openers?" page 3211 - page 3213	1-37
	--	

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

13 October 1998

Date of mailing of the international search report

30-10-1998

Name and mailing address of the ISA
 Swedish Patent Office
 Box 5055, S-102 42 STOCKHOLM
 Facsimile No. +46 8 666 02 86

Authorized officer

Gerd Strandell
 Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 98/00288

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Biochemical Pharmacology, Volume 47, No 8, 1994, B. Pirotte et al, "A Pyridothiadiazine (BPDZ 44) as a new and potent activator of ATP-Sensitive K ⁺ Channels" page 1381 - page 1386 --	1-37
X	EP 0618209 A1 (ADIR ET COMPAGNIE), 5 October 1994 (05.10.94) --	1-37
X	GB 1368948 A (MANUFACTURE DE PRODUITS PHARMACEUTIQUES A. CHRISTIAENS S.A.), 2 October 1974 (02.10.74) --	1-31, 36, 37
X	Metabolism, Volume 40, No 8, 1991, William D. Vlahos et al, "Diabetes Prevention in BB Rats by Inhibition of Endogenous Insulin Secretion" page 825 - page 829 -- -----	1-37

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 98/00288

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 32, 35
because they relate to subject matter not required to be searched by this Authority, namely:

Claims 32, 35 relate to methods of treatment of the human or animal body by surgery or by therapy. See PCT, Rule 39.1(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

27/07/98

International application No.

PCT/DK 98/00288

Patent document cited in search report			Publication date	Patent family member(s)	Publication date
WO	9726265	A1	24/07/97	AU 1437197 A	11/08/97
EP	0618209	A1	05/10/94	AU 673893 B	28/11/96
				AU 5904894 A	29/09/94
				CA 2119853 A	27/09/94
				FR 2703051 A,B	30/09/94
				JP 2513989 B	10/07/96
				JP 7002872 A	06/01/95
				NZ 260186 A	26/07/95
				US 5459138 A	17/10/95
				ZA 9402131 A	05/04/95
GB	1368948	A	02/10/74	AT 321301 B	25/03/75
				AT 324341 B	25/08/75
				BE 775166 A	10/05/72
				CA 1008859 A	19/04/77
				DE 2155483 A	08/06/72
				FR 2113927 A,B	30/06/72
				LU 64237 A	29/05/72
				NL 7115510 A	15/05/72
				US 3819639 A	25/06/74
				US 3980652 A	14/09/76
				US 3991057 A	09/11/76
				US 4002629 A	11/01/77